



Deposited via The University of Sheffield.

White Rose Research Online URL for this paper:

<https://eprints.whiterose.ac.uk/id/eprint/147522/>

Version: Accepted Version

---

**Article:**

Andrews, S.J., McFall, G.P., Booth, A. et al. (2019) Association of Alzheimer's disease genetic risk loci with cognitive performance and decline: A systematic review. *Journal of Alzheimer's Disease*, 69 (4). pp. 1109-1136. ISSN: 1387-2877

<https://doi.org/10.3233/JAD-190342>

---

The final publication is available at IOS Press through <http://dx.doi.org/10.3233/JAD-190342>

**Reuse**

Items deposited in White Rose Research Online are protected by copyright, with all rights reserved unless indicated otherwise. They may be downloaded and/or printed for private study, or other acts as permitted by national copyright laws. The publisher or other rights holders may allow further reproduction and re-use of the full text version. This is indicated by the licence information on the White Rose Research Online record for the item.

**Takedown**

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing [eprints@whiterose.ac.uk](mailto:eprints@whiterose.ac.uk) including the URL of the record and the reason for the withdrawal request.

# Association of Alzheimer's Disease Genetic Risk Loci with Cognitive Performance and Decline: A Systematic Review

Shea J. Andrews<sup>a,b,\*</sup>, G. Peggy McFall<sup>c,d</sup>, Andrew Booth<sup>e</sup>, Roger A. Dixon<sup>c,d</sup> and Kaarin J. Anstey<sup>f</sup>

<sup>a</sup>Centre for Research on Ageing, Health and Wellbeing, Australian National University, Canberra, Australia

<sup>b</sup>Department of Neuroscience, Icahn School of Medicine at Mount Sinai, New York, NY, USA

<sup>c</sup>Department of Psychology, University of Alberta, Edmonton, Canada

<sup>d</sup>Neuroscience and Mental Health Institute, University of Alberta, Edmonton, Canada

<sup>e</sup>School of Health and Related Research, University of Sheffield, Sheffield, UK

<sup>f</sup>School of Psychology, University of New South Wales and Lifecourse Ageing Research Centre, Neuroscience Research Australia, Sydney, New South Wales, Australia

Accepted 11 April 2019

**Abstract.** The association of *Apolipoprotein E* (*APOE*) with late-onset Alzheimer's disease (LOAD) and cognitive endophenotypes of aging has been widely investigated. There is increasing interest in evaluating the association of other LOAD risk loci with cognitive performance and decline. The results of these studies have been inconsistent and inconclusive. We conducted a systematic review of studies investigating the association of non-*APOE* LOAD risk loci with cognitive performance in older adults. Studies published from January 2009 to April 2018 were identified through a PubMed database search using keywords and by scanning reference lists. Studies were included if they were either cross-sectional or longitudinal in design, included at least one genome-wide significant LOAD risk loci or a genetic risk score, and had one objective measure of cognition. Quality assessment of the studies was conducted using the quality of genetic studies (Q-Genie) tool. Of 2,466 studies reviewed, 49 met inclusion criteria. Fifteen percent of the associations between non-*APOE* LOAD risk loci and cognition were significant. However, these associations were not replicated across studies, and the majority were rendered non-significant when adjusting for multiple testing. One-third of the studies included genetic risk scores, and these were typically significant only when *APOE* was included. The findings of this systematic review do not support a consistent association between individual non-*APOE* LOAD risk and cognitive performance or decline. However, evidence suggests that aggregate LOAD genetic risk exerts deleterious effects on decline in episodic memory and global cognition.

**Keywords:** Alzheimer's disease, cognition, genetic predisposition to disease, single nucleotide polymorphism

## INTRODUCTION

Cognitive performance generally declines with age, however, the patterns are characterized by 1) differences across cognitive domains and 2) substantial individual variation in level and trajectory [1, 2].

Performance on measures of episodic memory, executive function, reasoning, and processing speed may begin to decline in early adulthood whereas gradual improvement in some verbal and knowledge abilities may continue to the sixth or seventh decade of life [3]. Variation in individual trajectories reflects life-long differences in demographic, lifestyle, medical, environmental, neurobiological, and genetic factors [4].

\*Correspondence to: Shea Andrews, Icahn School of Medicine at Mount Sinai, 1425 Madison Ave, New York, NY, 10029, USA. Tel.: +1 212 659 8632; E-mail: shea.andrews@mssm.edu.

Cognitive decline is a multifactorial process that is likely promoted by the gradual accumulation of neuropathology associated with various chronic conditions of aging [5–7] and in particular late-onset Alzheimer's disease (LOAD) [8]. The accumulation of amyloid- $\beta$  (A $\beta$ ) and neurofibrillary tangles (NFT) begins decades prior to the onset of the clinical symptoms of LOAD [9–12]. In dementia-free individuals a higher burden of LOAD pathology is on average associated with reduced cognitive performance and faster rates of cognitive decline [13–15]. As such, age-related cognitive decline may be mediated by the co-occurrence of A $\beta$ , NFT, and other neuropathologies [16–18].

Genetic factors play an important role in the development of LOAD, accounting for 53% of the total phenotypic variance [19]. The *Apolipoprotein E* (*APOE*) epsilon ( $\epsilon$ 4) allele was the first common genetic variant associated with LOAD [20], with recent genome-wide association studies (GWAS) identifying a further 26 loci associated with LOAD (Supplementary Table 1). GWAS performed separately by four LOAD genetic consortia initially identified 11 loci (*ABCA7*, *BIN1*, *CD2AP*, *CD33*, *CLU*, *CRI*, *EPHA1*, *MS4A4A*, *MS4A4E*, *MS4A6A*, and *PICALM*) [21–25]. A further 12 loci (*HLA-DRB5*, *PTK2B*, *SORL1*, *SLC24A4-RIN3*, *INPP5D*, *MEF2C*, *NME8*, *ZCWPW1*, *CELF1*, *FERMT2*, and *CASS4*) were identified in a meta-analysis by the International Genomics of Alzheimer's Project (IGAP) [26]. A meta-analysis of IGAP and a proxy GWAS case-control study of self-reported family history of parental Alzheimer's dementia in 114 564 (14 482 proxy-cases & 100 082 proxy-controls) individuals from the UK Biobank identified a further 4 loci (*HBEGF*, *ECHDC3*, *SCIMP*, and *SPPL2A*) [27].

A trio of recent GWAS have identified a further 16 loci. A second meta-analysis of IGAP with an expanded UK Biobank dataset ( $n=314\,278$ ) identified three loci (*ADAM10*, *KAT8*, and *ACE*) [28]. A meta-analysis of UK Biobank proxy case-control status ( $n=376,113$ ), the personality genomics consortium Alzheimer's disease working group of the Psychiatric Genomics Consortium (PGC-ALZ,  $n=17,477$ ), IGAP ( $n=54,162$ ), and the Alzheimer's Disease Sequencing Project (ADSP,  $n=7,506$ ) identified 8 loci (*ADAMTS4*, *HESX1*, *CLNK*, *CNTAP2*, *APH1B*, *ABI3*, *ALPK2*, and *ACO74212.3*) [29]. Finally, an expanded IGAP analysis ( $n=94,437$ ) identified five loci (*OARD1*, *TREM2*, *IQCK*, *WVWX*, and *ADAMTS1*) [30]. *TREM2* and *ABI3*, however,

were identified as AD associated loci in an earlier rare variant analysis [31].

There is increasing interest in evaluating the role of LOAD genetic risk variants with cognitive decline. First, the shared cognitive and neuroanatomical characteristics of normal cognitive aging and the early stages of LOAD may be mediated by shared genetic mechanisms. The presence of individual LOAD-associated risk loci may lead to diminished overall cognitive function, in the absence of cognitive impairment or dementia, mediated by the gradual accumulation of LOAD pathology [13, 14]. Second, cognitive decline prior to dementia represents an important endophenotype for LOAD. Cognitive domain-specific variance reflects localized regional brain structures/networks and the connectivity of those networks. Therefore, the differential association of individual loci with specific cognitive domains may reflect associations with particular neuroanatomical structures that influence LOAD onset and progression.

Initial support for the association of LOAD risk loci with cognitive performance was obtained from studies assessing the association of *APOE* with cognition, where the *APOE* $\epsilon$ 4 allele was associated with specific deleterious effects on episodic memory, executive functioning, perceptual speed, and global cognitive ability [32, 33]. Further studies examining the association of other LOAD risk loci with cognitive function have been inconsistent and inconclusive. The aim of this systematic review is to evaluate the evidence of the association of non-*APOE* LOAD risk loci with cognitive performance and decline, within the context of both cognitive aging and a LOAD cognitive endophenotype. We provide a narrative synthesis rather than focusing on the relatively few studies that would be amenable to meta-analysis due to the heterogeneity in methodologies between studies.

## METHODS

### *Registration of protocol and reporting*

The protocol for the review was registered with the International Prospective Register of Systematic Reviews (PROSPERO CRD42017075685) [34] and the review is reported in accordance with the PRISMA checklist (see Supplementary Material).

Table 1  
Study Characteristics

Study	Cohort	Sample Size	Age (y)	Education (y)	% Male	Population Studied	Follow-up (y)	Cognitive Status
Andrews 2017 [41]	PATH	1,626	62.51 (1.51)	14.15	50.46	Caucasian	12	1,626 CN
Barral 2012 [90]	NIA-LOAD	1,365	72.9 (8.67)	14.5 (3)	60.1	Caucasian	—	337 AD, 1028 CN
Bressler 2017 [44]	ARIC	8,320	57 (5.6)	>11:86.1%	46.1	Caucasian	6	—
		2,039	55.8 (5.7)	>11:68.2%	33.7	African-American		
Carrasquillo 2015 [42]	Mayo Clinic	2,262	77 (49–98)*	14 (4–20)*	44	Caucasian	3.8 (0.7–17.8)*	At last diagnosis: 1881 CN, 252 MCI, 129 AD
Chibnik 2011 [57]	ROS MAP	791	75.5 (7.3)	18.1 (3.4)	34	Caucasian	7.8 (4.5)	218 incident AD
		875	81.0 (6.7)	14.3 (3.2)	27		4.3 (2.6)	186 incident AD
Christoforou 2014 [69]	NCNG	670	47.6 (18.3)	—	31.8	Caucasian	—	—
Darst 2017 [68]	WRAP	1,200	53.6 (6.6)	16.3 (2.8)	31.1	Caucasian	6.2	CN; enriched with a family history of AD
Davies 2014 [89]	<b>CAGES</b>	3,280	—	—	—	Caucasian	—	Non-demented
	LBC1921</b>	453	79.1 (0.6)	—	41		68	
	LBC1936</b>	932	69.5 (0.8)	—	51		59	
	ABC1936</b>	347	64.6 (0.9)	—	52		53	
	Manchester and Newcastle	1,548	65 (44–93)*	—	29		14 (12–18)*	
Davies 2015 [61]	CHARGE	53,949	66.39 (44.2)	—	42.7	Caucasian	—	53,949 CN
Davies 2016 [58]	UK Biobank	112,151	56.91 (7.93)	30.5% w/ college degree	47.5	Caucasian	—	—
Davies 2018 [39]	UKBB, CHARGE, COGENT	300,486	56.76	—	46.26	Caucasian	—	Dementia Free at baseline
DeBette 2015 [56]	CHARGE	29,076	63.6 (7.0)	28.8% w/ college degree	44	Caucasian	—	29,076 CN
DeJager 2012 [78]	ROS	749	75.3 (7.2)	18.2 (3.4)	34	Caucasian	9	CN at Baseline. At last diagnosis: 151 MCI; 152 Dementia
Engelman 2013 [43]	WRAP	1,153	53.6 (6.6)	≥college 62%	31	Caucasian	UTAI 8	CN at baseline; Enriched for a parental history of AD
Ferencz 2014 [70]	SNAC-K	2 480	71.69 (10.3)	12.29 (4.3)	34.1	Swedish	—	CN at baseline
Ge 2018 [75]	ADNI	702	72.8	16.3	54.6	Caucasian	2.83	Baseline: 221 CN; 367 MCI, 114 AD
Gui 2014 [88]	GBCS					Chinese	4	CN at baseline; 198 incident Neurological disease
	Cases	1 325	62.4 (7.0)	≥College 9%	31.5			
	Controls	1 083	65.4 (4.5)	≥College 17.1%	32.4			
Hagenaars 2016 [95]	UK Biobank	112 151	56.9 (7.9)	30.5% w/ degree	47.5	British	—	—
Hagenaars 2017 [50]	UK Biobank	23 822	—	—	—	British	—	—
Hamilton 2011 [47]	LBC1921	505	10.9 (0.28)	—	41.3	Caucasian	68.21	CN
	LBC1936	998	10.9 (0.28)	—	50.5		58.68	

(continued)

Table 1  
(continued)

Study	Cohort	Sample Size	Age (y)	Education (y)	% Male	Population Studied	Follow-up (y)	Cognitive Status
Harris 2014 [96]	<b>CAGES</b>					Caucasian		
	LBC1921</b>	550	79.1 (0.6)	—	42.5		68.21	CN
	LBC1936	1 091	69.5 (0.8)	—	50.2		58.68	
	ABC1936</b>	498	64.6 (0.9)	—	48.8		53.7	
	Manchester and Newcastle	6,063	44–93	—	30.1		20	
Hill 2018 [40]	UKBB	120 934	—	—	—	—	—	—
	SSAGC	329 417						
	Sniekers 2017	78 308						
Houlihan 2009 [62]	LBC1936	1 031	69.5 (0.8)	—	50.3	Scottish	58.68	CN
Keenan 2012 [94]	ROS	817	75.7 (7.4)	18.2 (3.4)	34.4	Caucasian	—	Dementia free at baseline, 240 incident dementia
	MAP	892	81.1 (6.7)	14.7 (2.9)	27.6	Caucasian	—	27.8% CN; 48.9% MCI; 23.3% AD
	ADNI	746	75.4 (6.9)	15.6 (3.0)	59		—	11.6% AD
	CHAP	624	71.9 (5.2)	14.9 (3.3)	37	Caucasian	—	
Liang 2015 [97]	BABRI	780	64.7 (7.2)	11.3 (3.2)	37.1	Chinese	—	Cognitively Normal
Liao 2014 [87]	Taiwan Biobank	307	76.2 (10)	10.7 (4.9)	69.4	Chinese	—	Cognitively Normal
Liebers 2016 [73]	HRS	8 616	60.5 (8.5)	≥college 25.2%	43.8	Caucasian	10 (0–14)	—
Li 2017 [64]	BABRI	780	64.7 (7.3)	11.3 (3.2)	37.1	Chinese	—	CN
Liu 2009 [65]	Rotterdam	2 583	64.0 (5.8)	—	42.9	Caucasian	—	CN
	Study ERF	2 883	48.7 (14.5)	—	40.0		—	
Liu 2014 [67]	ADNI	211	75.6 (4.9)	16.1 (2.8)	54	—	—	CN
Marden 2016 [71]	HRS	7 172	63.0 (8.4)	13.1 (2.5)	40.8	Caucasian	12.3	—
		1 081	61.6 (8.0)	11.4 (3.3)	33.7	African-American	11.3	
Marioni 2017 [74]	Generation Scotland	3 495	63 (61–65)†	12 (3–15)†	42.8	Scottish	—	CN
McFall 2016 [92]	VLS	593	70.3 (8.66)	15.3 (2.95)	32.7	Canadian	UTAI 9	CN
Mengel-From 2011 [54]	Danish 1905 Cohort Study	1 380	92–93	—	31	Danish	—	At baseline: 48.64% non-impaired; 32.06% Mildly Impaired; 19.30% Severely Impaired
Mengel-From 2013 [55]	Danish 1905 Cohort Study	1 651	92–93	—	—	Danish	7 10	At baseline: 47.3% CN
	LSADT	573	73–83	—	—		—	At baseline: 80.7% CN
Mormino 2016 [72]	ADNI	526	75.3 (6.5)	15.9 (2.9)	61.8	Caucasian	4.58 (2.74)	36.9% CN; 63.1% MCI
Nettiksimmons 2016 [45]	MrOS SOF	3 267	73.4 (5.7)	56% w/ college degree	100 0	Caucasian	UTAI 10	—
		3 026	71.0 (4.9)	18% w/ college degree			UTAI 10	
Pedraza 2014 [52]	Mayo Clinic	268 2	78.7 (7.4)	12.6 (3.0)	23	African American	—	CN: 224; AD: 44
		651	81.8 (6.3)	14.0 (2.9)	43.7	Caucasian	—	CN: 2219; AD: 431
Qiu 2016 [93]	—	46	62.96	—	39.1	Chinese	—	Dementia free at baseline
Raj 2017 [59]	CHAP	2 588	70.4 (5.0)	11.9 (3.2)	37	African-American	UTAI 12	Dementia free at baseline
	IIDP	1 178	75.5 (5.5)	11.0 (2.9)	34		UTAI 15	
	ROS/MAP	85	70.5 (7.6)	15.4 (3.4)	16		UTAI 19	
	MARS	113	76.9 (5.1)	14.8 (4.1)	39		UTAI 17	
Reynolds 2013 [66]	SATSA	1,609	72.3 (50.1–93)*	—	42.3	Swedish	7.8 (0–17.8)*	Dementia free at baseline
	OCTO-Twin GENDER							

Savage 2018 [38]	UKBB, Cogent, GENR, S4S, TEDS, DTR, IMAGEN, BLTS, NESCOG, GfG, FHS, STR, HRS/HI IQ, RS, STSA	269 867	52.87	—	46.26	Caucasian	—	—
Shulman 2010 [91]	ROS	414	87.1 (6.9)	16.5 (3.6)	38.9	United States	—	Dementia free at baseline; 98 incident MCI; 185 incident dementia
Sneikers 2017 [60]	MAP UKBB, GENR, TEDS, ALSPAC, QIMR, RAINE, HU, ERF, STR, LBC1921, LBC1936	78 308	44.4	—	—	Caucasian	—	—
Sweet 2012 [53]	CHS	1 831	71.7 (4.7)	39.9% w/ some college	37.5	Caucasian	UPTAI 9	Dementia free at baseline
Thambisetty 2013 [51]	BLSA	599	67.5 (7.5)	16.5 (2.5)	57.1	22.4% African-American	6.6 (4.6)	CN
		95	75.9 (7.1)	16.2 (3.1)	56.8	77.6% Caucasian	5.4 (4.2)	MCI/AD converters
Verhaaren 2013 [48]	Rotterdam Study	5 171	66.2 (11.2)	12.8% primary education only	43.6	Dutch	—	Dementia free at baseline
Vivot 2015 [46]	3C	4 931	74.0 (70.0–78.2)†	36% >9 years	38	French	UTAI 10	Dementia free at baseline
Zhang 2014 [49]	HRS	5 808	64.0 (7.3)	≥ college 21.8%	42.8	Caucasian	UTAI 13	—

\*Median (range); †Median (IQR); UTAI, Up to and Including.

### Search strategy

A PubMed database search (see Supplementary Material) included papers published between January 2009 (the publication year of the first GWAS to identify non-*APOE* genome-wide significant SNPs for LOAD) and April 2018 (inclusive). Articles were restricted to human studies published in English. Reference lists of all articles selected for data extraction were screened for additional articles.

### Inclusion and exclusion criteria

Studies were included in the review if they met the following inclusion criteria: 1) included genetic data from non-*APOE* genome-wide significant risk loci for LOAD (*ABCA7*, *BINI*, *CD2AP*, *CD33*, *CLU*, *CR1*, *EPHA1*, *MS4A4A*, *MS4A4E*, *MS4A6A*, *PICALM*, *HLA-DRB*, *PTK2B*, *SORL1*, *SLC24A4*, *RIN3*, *INPP5D*, *MEF2 C*, *NME8*, *ZCWPW1*, *CELF1*, *FERMT2*, *CASS4*, *HBEGF*, *ECHDC3*, *SPPL2A*, and *SCIMP*) or a LOAD genetic risk score (GRS); 2) included at least one test measuring cognitive performance; 3) the publication was in English; 4) it was either cross-sectional or longitudinal. Articles were excluded if they were: 1) case only studies, case reports or review articles; 2) animal studies; or 3) conducted in a clinical population.

### Abstract screening and article selection

Article citations and abstracts were imported into Covidence [35], rated against the selection criteria, and nominated independently for inclusion in full-text screening by SJA and GPM. Subsequently, full-text articles were assessed for inclusion in the final review. When the two reviewers differed, the article was discussed until a consensus was reached. Inter-rater reliability was assessed by calculating a two-way consistency average-measures interclass correlation coefficient (ICC).

### Data extraction

For articles included in the systematic review, the following variables were extracted: 1) study design (i.e., longitudinal or cross-sectional; candidate SNPs, gene-based or GWAS analysis; statistical test); 2) sample characteristics (i.e., sample size, age, education, gender, ethnicity/population, follow-up, and cognitive status); 3) genetic variants examined; 4) cognitive tests examined; and 5) reported associa-

tions (i.e., non-significant result, positive association, negative association). Given the heterogeneity in the measures with which the reviewed articles assessed cognitive performance, all the cognitive tests were coded within conventional cognitive domains [33] (Supplementary Table 2). These domains are based on the typical taxonomy found in the neuropsychological literature and were used in previous previous meta-analyses on the effect of *APOE* on cognitive performance [33, 36]. Cognitive domains included: attention (AT), episodic memory (EM), executive function (EF), global cognition (GC), perceptual speed (PS), working memory (WM), verbal ability (VA), and visuospatial skill (VS). Two general cognition clusters were included: fluid cognition (Gf) and crystallized cognition (Gc). Study quality was evaluated using the 11-item Quality of Genetic Studies (Q-Genie) Tool [37] (Supplementary Material).

### Novel AD loci

The initial screen did not include the 16 novel loci identified by Marioni et al. [28], Janssen et al. [29], and Kunkle et al. [30] (*ADAM10*, *KAT8*, *ACE*, *ADAMTS4*, *HESX1*, *CLNK*, *CNTAP2*, *APH1B*, *ABI3*, *ALPK2*, *ACO74212.3*, *OARD1*, *TREM2*, *IQCK*, *WWOX*, and *ADAMTS1*) as these studies were published after the database search and article screening were conducted. As such, for the loci reported in these studies we limited our search to articles citing either the BioRxiv pre-print article or the published article as of March 2019. Additionally, where GWAS summary statistics were available for cognitive phenotypes, we extracted the reported associations for these loci.

## RESULTS

### Systematic literature search

The PubMed search identified 2,446 references and follow-up screening of reference lists identified two additional articles. 2,395 references were removed based on the inclusion/exclusion criteria. Seventy-one full-text articles were reviewed, 21 were excluded as follows: 1) fifteen due to selected AD risk loci not reported, 2) one was an updated analysis of a previous study, 3) two because summary statistics were not made publicly available, 4) three as the study was conducted in adolescents. Forty-nine articles were included in the systematic review (Supplementary Figure 1).

Table 2  
Description of the Methods used for each study

Study	Study Design	Genetic risk Score	Gene Symbols	Cognitive Domains	Statistical Test
Andrews 2017 [41]	Longitudinal, candidate SNPs	Unweighted & weighted GRS w/ & w/o APOE	ABCA7, BIN1, CD2AP, CD33, CLU, CR1, EPHA1, MS4A4A, MS4A4E, MS4A6A, PICALM, HLA-DRB5, PTK2B, SORL1, SLC24A4-RIN3, INPP5D, MEF2C, NME8, ZCWPW1, CLEF1, FERMT2, CASS4	EM, EF, VA, PS	Linear Mixed Effects Models
Barral 2012 [90]	Cross-sectional, candidate SNPs	—	BIN1, CLU, CR1, PICALM	EM	Logistic Regression
Bressler 2017 [44]	Longitudinal, Candidate SNPs	Unweighted GRS w/ APOE	ABCA7, BIN1, CASS4, CD2AP, CD33, CELF1, CLU, CR1, EPHA1, FERMT2, HLA-DRB1, INPP5D, MEF2C, MS4A4E, NME8, PICALM, PTK2B, SLC24A4, SORL1, ZCWPW1	EM, PS, VA	General Linear Models
Carrasquillo 2015 [42]	Longitudinal, candidate SNPs	Weighted GRS w/ & w/o APOE	ABCA7, BIN1, CD2AP, CD33, CLU, CR1, EPHA1, MS4A6A, PICALM	EM	Linear Mixed Effects Models
Chibnik 2011 [57]	Longitudinal, candidate SNPs	—	CLU, CR1, PICALM	EM, GC, WM, VA, PS, VS cognitive composites	Linear Mixed Effects Models
Christoforou 2014 [69]	Cross-sectional, GWAGS	—	ABCA7, CLU, BIN1, CD2AP, CD33, CR1, EPHA1, MS4A4A, MS4A6A, MS4A4E, PICALM, HLA-DRB5, PTK2B, SORL1, SLC24A4, RIN3, INPP5D, MEF2C, ZCWPW1, FERMT2, CASS4, HBEFG, ECHDC3, SCIMP, SPPL2A, ADAM10, KAT8, ACE, ADAMTS4, HESX1, CLNK, CNTAP2, APH1B, ABI3, ALPK2, OARD1, TREM2, IQCK, WWOX, ADAMTS1	Gf, Gc	Gene - PLINK permutation-based tests
Darst 2017 [68]	Longitudinal, candidate SNPs	Weighted pathway specific GRS w/ & w/o APOE	ABCA7, BIN1, CD2AP, CLU, CR1, EPHA1, MS4A6A, PICALM, HLA-DRB1, PTK2B, SORL1, SLC24A4, INPP5D, NME8, ZCWPW1, CLEF1, FERMT2, CASS4, MEF2C	EM, WM, PS/EF factor scores	Linear Mixed Effects Models
Davies 2014 [68]	Longitudinal, GWAS	—	ABCA7, BIN1, CD2AP, CD33, CLU, CR1, MS4A6A, PICALM	Gf	Growth Curve Models

(continued)

Table 2  
(continued)

Study	Study Design	Genetic risk Score	Gene Symbols	Cognitive Domains	Statistical Test
Davies 2015 [61]	Cross-sectional, gene-based	—	ABCA7, BIN1, CD2AP, CD33, CLU, CR1, EPHA1, MS4A6A, PICALM, HLA-DRB1, HLA-DRB5, PTK2B, SORL1, SLC24A4, RIN3, INPP5D, MEF2C, ZCWPW1, FERMT2, CASS4	Gf	
Davies 2016 [58]	Cross-sectional, GWAS	—	ABCA7, BIN1, CASS4, CD2AP, CD33, CELF1, CLU, CR1, EPHA1, FERMT2, HLA-DRB5–HLA-DRB1, INPP5D, MEF2C, MS4A6A, NME8, PICALM, PTK2B, SLC24A4-RIN3, SORL1, ZCWPW1	EF, PS, EM	
Davies 2018 [39]	Cross-sectional, GWAS; GWAGS	—	ABCA7, BIN1, CASS4, CD2AP, CELF1, CD33, CLU, CR1, EPHA1, FERMT2, HLA-DRB5, INPP5D, MS4A6A, MS4A4A, MS4A4E, MEF2C, NME8, PICALM, PTK2B, SORL1, SLC24A4-RIN3, ZCWPW1, HBEGF, SPPL2A, ECHDC3, SCIMP, ADAM10, KAT8, ACE, ADAMTS4, HESX1, CLNK, CNTAP2, APH1B, ABI3, ALPK2, OARD1, TREM2, IQCK, WWOX, ADAMTS1, AC074212.3	GC	Linear Regression
DeBette 2015 [56]	Cross-sectional, GWAS	Weighted GRS w/ & w/o APOE	CLU, EPHA1, CD2AP, PICALM, MS4A6A, BIN1, CD33, CR1, ABCA7, PTK2B, SORL1, SLC24A4, INPP5D, MEF2C, NME8, ZCWPW1, CELF1, FERMT2, CASS4	EM	Linear Regression
DeJager 2012 [78]	Longitudinal, GWAS	Weighted GRS w/o APOE	CR1, PICALM, CLU, BIN1, ABCA7, MS4A, CD2AP, EPHA1, CD33	GC cognitive composite	Linear Mixed Effects Models: Modelled Change Linear regression for GWAS
Engelman 2013 [43]	Longitudinal, candidate SNPs	—	ABCA7, BIN1, CD2AP, CD33, CLU, CR1, EPHA1, MS4A, PICALM	EM, WM, EM factor scores	Linear Mixed Models

Ferencz 2014 [70]	Cross-sectional, candidate SNPs	Unweighted GRS	PICALM, CLU, BIN1	EM, PS, VA	ANCOVA
Ge 2018 [75]	Longitudinal	Weighted PGRS w/ APOE	—	EM, EF	Linear Mixed Effects Models
Gui 2014 [88]	Longitudinal, candidate SNPs	Weighted GRS w/ APOE	BIN1, CD2AP, CLU, SORL1, PICALM, MS4A6A, MS4A4E, ABCA7, CD33	EM	Maximum Likelihood multiple linear regression
Hagenaars 2016 [95]	Cross-sectional	PGRS	—	EF, PS, EM	Linear Regression
Hagenaars 2017 [50]	Cross-sectional; GWAS; GWAGS	—	ABCA7, BIN1, CASS4, CD2AP, CD33, CELF1, CLU, CR1, EPHA1, FERMT2, HLA-DRB1, MEF2C, MS4A4A, MS4A4E, MS4A6A, NME8, PICALM, PTK2B, SLC24A4, ZCWPW1, HBEFG, ECHDC3, SCIMP, SPPL2A, ADAM10, KAT8, ACE, ADAMTS4, HESX1, CLNK, CNTAP2, APH1B, ABI3, ALPK2, OARD1, TREM2, IQCK, WWOX, ADAMTS1	AT, EF	Linear Regression
Hamilton 2011 [47]	Longitudinal, candidate SNPs	—	BIN1, CLU, CR1, PICALM	GC, VA, EF, EM	ANOVA
Harris 2014 [96]	Longitudinal	PGRS	—	Gf, Gc, PS, EM	Partial Correlations
Hill 2018 [40]	Cross-sectional, GWAS; GWAGS	—	ABCA7, MEF2C, HBEFG, CELF1, ZCWPW1, SPPL2A, HLA-DRB1, SLC24A4, HLA-DRB5, SORL1, PICALM, CR1, RIN3, ECHDC3, FERMT2, SCIMP, INPP5D, BIN1, CLU, PTK2B, CD2AP, MS4A4E, CD33, CASS4, MS4A4A, EPHA1, MS4A6A, NME8, ADAM10, KAT8, ACE, ADAMTS4, HESX1, CLNK, CNTAP2, APH1B, ABI3, ALPK2, OARD1, TREM2, IQCK, WWOX, ADAMTS1, AC074212.3	GC	Multi-Trait Analysis of GWAS (MTAG)
Houlihan 2009 [62]	Cross-sectional, candidate SNPs	—	SORL1	GC, EM, WM, EF, VS, VA, PS	Linear Regression
Keenan 2012 [94]	Longitudinal, candidate SNPs	—	CR1	EM cognitive composite	Linear Mixed Effects Models

(continued)

Table 2  
(continued)

Study	Study Design	Genetic risk Score	Gene Symbols	Cognitive Domains	Statistical Test
Liang 2015 [97]	Cross-sectional, candidate SNPs	—	SORL1	GC, EM, EM, VS, VA, PS, EF	MANOVA
Liao 2014 [87]	Cross-sectional, candidate SNPs	—	ABCA7	GC	ANOVA
Liebers 2016 [73]	Longitudinal	PGRS	—	GC, AT, EM	Linear Mixed Effects Models
Li 2017 [64]	Cross-sectional, candidate SNPs	—	SORL1	GC, EM, VS, VA, PS, EF	GLM
Liu 2009 [65]	Cross-sectional, candidate SNPs	—	SORL1	EM, EF, GC cognitive composites	GLM
Liu 2014 [67]	Longitudinal, candidate SNPs	—	NME8	GC, EM	ANOVA
Marden 2016 [71]	Longitudinal	Weighted GRS w/ & w/o APOE	BIN1, CLU, ABCA7, CR1, PICALM, MS4A6A, CD33, CD2AP, EPHA1, HLA, PTK2B, SORL1, SLC24A4, INPP5D, MEF2C, NME8, ZCWPW1, CELF1, FERMT1, CASS4	EM	Linear regression
Marioni 2017 [74]	Cross-sectional	PGRS	—	PS, EM	Linear Mixed Effects Models
McFall 2016 [92]	Longitudinal, candidate SNPs	—	CLU	EF factor scores	Growth curve models
Mengel-From 2011 [54]	Cross-sectional, candidate SNPs	—	CLU, PICALM, CR1	GC	Linear Regression
Mengel-From 2013 [55]	Longitudinal, candidate SNPs	—	CLU	GC	Linear Mixed Effects Models
Mormino 2016 [72]	Longitudinal	PGRS	—	EM, EF factor scores	Linear Mixed Effects Models
Nettiksimmons 2016 [45]	Longitudinal, candidate SNPs, gene-based	—	ABCA7, BIN1, CASS4, CD2AP, CD33, CELF1, CLU, CR1, EPHA1, FERMT2, HLA, INPP5D, MEF2C, MS4A, NME8, PICALM, PTK2B, SLC24A4, SORL1, ZCWPW1	GC	Linear Mixed Effects Models
Pedzara 2014 [52]	Cross-sectional, candidate SNPs	—	CLU, CR1, PICALM	EM	Linear Regression
Qiu 2016 [93]	Cross-sectional, candidate SNP	—	CLU	GC, PS, VA	t-test

Raj 2017 [59]	Longitudinal, GWAS	—	ABCA7, MS4A6A, CASS4, INPP5D, SORL1	GC cognitive composite	Linear Mixed Effects Models
Reynolds 2013 [66]	Longitudinal, candidate SNPs	—	SORL1	VA, EM, PS, WM	Linear Mixed Effects Models
Savage 2018 [38]	Cross-sectional, GWAS; GWAGS	—	MEF2C, HBEGF, SPPL2A, SLC24A4, CR1, CELF1, RIN3, ZCWPW1, ECHDC3, CLU, ABCA7, PICALM, SORL1, BIN1, INPP5D, EPHA1, CASS4, MS4A4E, SCIMP, MS4A6A, CD2AP, MS4A4A, FERMT2, PTK2B, CD33, NME8, <i>ADAM10</i> , <i>KAT8</i> , <i>ACE</i> , <i>ADAMTS4</i> , <i>HESX1</i> , <i>CLNK</i> , <i>CNTAP2</i> , <i>APH1B</i> , <i>ABI3</i> , <i>ALPK2</i> , <i>OARD1</i> , <i>TREM2</i> , <i>IQCK</i> , <i>WVVOX</i> , <i>ADAMTS1</i> , <i>AC074212.3</i>	GC	Gene test
Shulman 2010 [91]	Cross-sectional, candidate SNPs	—	SORL1, CD33	EM, VA, WM, PS, VS cognitive composites	Linear Regression
Sneikers 2017 [60]	Cross-sectional, GWAS; GWAGS	—	MEF2C, HBEGF, CELF1, ZCWPW1, MS4A4E, MS4A6A, SLC24A4, PICALM, MS4A4A, SCIMP, CD2AP, HLA-DRB1, SORL1, PTK2B, CD33, NME8, CR1, HLA-DRB5, BIN1, SPPL2A, ECHDC3, EPHA1, CLU, CASS4, ABCA7, RIN3, FERMT2, <i>ADAM10</i> , <i>KAT8</i> , <i>ACE</i> , <i>ADAMTS4</i> , <i>HESX1</i> , <i>CLNK</i> , <i>CNTAP2</i> , <i>APH1B</i> , <i>ABI3</i> , <i>ALPK2</i> , <i>OARD1</i> , <i>TREM2</i> , <i>IQCK</i> , <i>WVVOX</i> , <i>ADAMTS1</i> , <i>AC074212.3</i>	GC	Regression
Sweet 2012 [53]	Longitudinal, candidate SNPs	—	CLU, CR1, PICALM	GC, AT	Bayesian Modelling
Thambisetty 2013 [51]	Longitudinal, candidate SNPs	—	CLU	EM	Linear Mixed Effects Models
Verhaaren 2013 [48]	Cross-sectional, candidate SNPs	Weighted GRS w/ & w/o APOE	CLU, PICALM, BIN1, CR1, ABCA7, MS4A6A, MS4A4E, CD2AP, EPHA1, CD33	GC, EM, EF, PS cognitive composites	Linear Regression
Vivot 2015 [46]	Longitudinal, candidate SNPs	Weighted GRS w/ & w/o APOE	CR1, CLU, BIN1, PICALM, ABCA7, MS4A4E, CD33, MS4A6A, CD2AP	GC, VA, GC, PS, EM	non-linear mixed models with latent processes
Zhang 2014 [49]	Longitudinal, GWAS	—	PICALM, CD2AP, CR1, EPHA1, MS4A, CLU, CD33, ABCA7, BIN1	GC	Linear Mixed Effects Models

For each study we report study characteristics (Table 1), study design (Table 2), individual cognitive tests and the respective cognitive domains tested (Supplementary Table 2), and individual SNPs genotyped (Supplementary Table 3). Of the forty-nine studies, 23 employed a cross-sectional design and 26 a longitudinal design. 29 selected SNPs based on a candidate gene approach, 7 employed gene-based analyses, 6 reported AD risk loci as a secondary outcome in GWAS, and 17 included a GRS, with 8 studies only using a GRS. Episodic memory ( $n=31$ , 63.27%) and global cognition ( $n=23$ , 46.94%) were the most commonly assessed cognitive measures.

The overall average quality rating was 'good', with four studies obtaining a 'moderate' score. The distribution and mean rating for each item and the average score per study are presented in Supplementary Figures 2 and 3. The ICC was in the excellent range (ICC=0.88 95%CI: 0.79 - 0.93), indicating that reviewers had a high degree of agreement in the overall quality of the included studies.

#### Association of AD genetic risk loci with cognitive performance and change

In the following narrative, we report all gene-cognition associations that are statistically significant ( $p<0.05$ ) (Figs. 1 and 3). However, it should be noted that the majority (84.3%) of the reported associations were non-significant (Supplementary Table 4). The number of studies investigating the association of each LOAD loci with cognitive function and the number of studies reporting at least one significant association for each gene-cognitive domain combination is reported in Supplementary Table 4. Across cognitive domains/clusters, GC had the highest proportion of reported significant associations (30.2%, 77/255) followed by VS (30%, 3/10), VA (14.29%, 16/112), EM (14.29%, 32/224), AT (13.33%, 6/45), EF (11.86%, 14/118), PS (11.79%, 23/195), Gf (7.46%, 5/67), WM (4.05%, 3/74), and Gc (0%, 0/38). The largest studies to report an association between the AD risk loci and GC, were two GWAS meta-analyses inclusive of the UK Biobank ( $n=269,867$  and  $300,486$ ) [38, 39] and a multi-trait analysis of intelligence and educational attainment ( $n=248,482$ ) [40]. Davies et al. [39] found 18 loci associated with GC (*MEF2C*, *HBEGF*, *SPPL2A*, *IQCK*, *ABI3*, *FERMT2*, *CELF1*, *CR1*, *CNTNAP2*, *SLC24A4*, *AC074212.3*, *CLU*, *ABCA7*, *ADAM10*, *PTK2B*, *CD2AP*, *CLNK*, and *WVVOX*), of which only

*MEF2C*, *HBEGF*, and *SPPL2A* were genome-wide significant. Savage et al. found 11 loci to be associated with GC (*MEF2C*, *HBEGF*, *SPPL2A*, *CR1*, *SLC24A4*, *OARD1*, *CNTNAP2*, *WVVOX*, *ZCWPW1*, *CELF1*, and *ABCA7*), of which *MEF2C*, *HBEGF*, and *SPPL2A* were also genome-wide significant [38]. Finally, Hill et al. [40] identified 13 loci associated with global cognition (*MEF2C*, *HBEGF*, *CELF1*, *ZCWPW1*, *SPPL2A*, *WVVOX*, *HLA-DRB1*, *SLC24A4*, *ADAMTS4*, *ALPK2*, *ACE*, *SORL1*, and *PICALM*), of which *MEF2C*, *HBEGF*, *CELF1*, and *ZCWPW1* were genome wide significant.

#### ABCA7

rs3764650(G) was associated with worse baseline performance and slower decline in EM [41]. In a second study, rs3764650(C) was associated with faster decline in EM in cognitively normal participants who converted to mild cognitive impairment (MCI)/Alzheimer's disease (AD), but not in participants who remained cognitively normal [42]. Additionally, rs3752246(G) was associated with worse performance in EM and WM at baseline [43], whereas rs4147929(A) was associated with better baseline EM [44] and EF [39] performance. Change in GC was associated with rs115550680(G) in African-Americans and with the *ABCA7* gene-region in a female only and a male only cohort [45].

#### BIN1

rs744373(G) was associated with worse baseline EM performance [41] and a faster rate of decline in global cognition [46]. In univariate (7 SNPs) and haplotype analyses (two 3-SNP windows), significant associations were observed for cognitive performance in EM, EF, VA, and GC [47]. The *BIN1* gene region was associated with change in GC in females [45].

#### CD2AP

rs9349407(C) and rs9296559(G) were associated with worse EM performance and a faster rate of decline in GC respectively [48, 49]. The *CD2AP* gene region was also associated with performance in AT [50] and PS [39].

#### CD33

rs3865444(C) was associated with worse baseline performance in EF [48], and in African-Americans rs3865444(A) was associated with worse baseline performance in VA [44]. The *CD33* gene region and

Gene	Metric	Cognitive Domain									
		AT	EM	EF	VA	PS	WM	VS	GC	gF	gC
ABCA7	Baseline	•	↓ <sup>41</sup> ↑ <sup>44</sup> ↓ <sup>43</sup> •42,68,58,56,48,46	↑ <sup>39</sup> •50,58,48	•41,44,46	•41,44,68,58,48,46,39	↓ <sup>43</sup> •41,68	—	•48,46,87,40,38,60,39	•69,61	•69
	Slope	—	↓ <sup>42</sup> •41,44,46,88	—	•41,44,46	↑ <sup>41</sup> •44,46	•41	—	↑ <sup>45</sup> ↑ <sup>59</sup> •46,49,78	•89	—
BIN1	Baseline	•50	↓ <sup>41</sup> ↑ <sup>47</sup> •44,43,42,68,58,56,48,46,90	↑ <sup>47</sup> •50,58,48,39	↑ <sup>47</sup> •41,44,46	•41,44,68,58,48,46,39	•41,43,68	—	•48,46,40,38,60,39	•69,61	•69
	Slope	—	•41,44,42,46,88	—	•41,44,46	•41,44,46	•41	—	↑ <sup>47</sup> ↑ <sup>45</sup> ↓ <sup>46</sup> •46,78	•89	—
CD2AP	Baseline	↑ <sup>50</sup>	↓ <sup>48</sup> •41,44,43,42,68,58,56,46	•50,58,48,39	•41,44,46	•41,44,68,58,48,46	•41,43,68	—	•48,46,40,38,60,39	•69,61	•69
	Slope	—	•41,44,42,46,88	—	•41,44,46	•41,44,46	•41	—	↓ <sup>49</sup> •46,45,78	•89	—
CD33	Baseline	•50	•41,44,43,42,58,56,48,46,91	↓ <sup>48</sup> •50,58,39	↓ <sup>44</sup> •41,46,91	•41,44,58,48,46,91,39	•41,43,91	•91	•48,46,91,40,38,60,39	•69,61	•69
	Slope	—	•41,44,42,46,88	—	•41,44,46	•41,44,46	•41	—	↑ <sup>45</sup> •46,49,78	•89	—
CLU	Baseline	•50,53	↑ <sup>44</sup> ↓ <sup>42</sup> ↑ <sup>68</sup> ↓ <sup>56</sup> ↑ <sup>47</sup> ↑ <sup>52</sup> •41,43,58,48,46,90	•50,58,48,47,92,39	↑ <sup>47</sup> •41,44,46,93	•41,44,68,58,48,46,39,93	•41,43,68	—	↑ <sup>54</sup> ↑ <sup>55</sup> •46,47,53,93 •40,38,60,39	•69,61	•69
	Slope	•53	↓ <sup>51</sup> •41,44,42,46,88,57	•92	•41,44,46,57	↑ <sup>44</sup> •41,46,57	↑ <sup>41</sup> •57	•57	↑ <sup>55</sup> ↓ <sup>53</sup> •46,45,49,78,57	•89	—
CR1	Baseline	•50,53	↓ <sup>52</sup> •41,44,43,42,68,58,56,48,46,47,90	•50,58,48,47,39	↑ <sup>47</sup> •41,44,46	↑ <sup>44</sup> ↑ <sup>39</sup> •41,68,58,48,46	•41,43,68	—	↑ <sup>47</sup> ↑ <sup>38</sup> ↑ <sup>39</sup> •48,46,53,54,40,60	•69,61	•69
	Slope	↓ <sup>53</sup>	↓ <sup>94</sup> ↓ <sup>57</sup> •41,44,42,46	—	↓ <sup>46</sup> ↓ <sup>57</sup> •41,44	↓ <sup>57</sup> •41,44,46	•41,57	↓ <sup>57</sup>	↑ <sup>45</sup> ↓ <sup>78</sup> ↓ <sup>57</sup> •46,49,53	•89	—
EPHA1	Baseline	•50	↓ <sup>48</sup> •41,44,43,42,68,58,56	•50,58,48,39	•41,44	•41,44,68,58,48,39	•41,43,68	—	•48,40,38,60,39	•69,61	•69
	Slope	—	↓ <sup>42</sup> •41,44	—	•41,44	•41,44	—	—	•45,49,78	—	—
MS4A	Baseline	•50	↓ <sup>58</sup> •41,44,42,68,56,43,48,46	•50,58,48,39	↑ <sup>41</sup> •44,46	•41,44,68,58,48,46,39	•41,43,68	—	•48,46,40,38,39	•69,61	•69
	Slope	—	↑ <sup>44</sup> •41,42,46,88	—	•41,44,46	•41,44,46	•41	—	↑ <sup>60</sup> ↑ <sup>59</sup> •46,45,49,78	•89	—
PICALM	Baseline	•50,53	•41,44,43,42,68,58,56,48,46,47,90,52	↑ <sup>47</sup> •50,58,48,39	•41,44,47,46	•41,44,68,58,48,46,39	•41,43,68	—	↑ <sup>47</sup> ↑ <sup>54</sup> ↓ <sup>53</sup> ↑ <sup>40</sup> •48,46,38,60,39	•69	•69
	Slope	•53	↓ <sup>57</sup> •41,44,42,46,88	—	↓ <sup>57</sup> •41,44,46	•41,44,46,57	•41,57	•57	↑ <sup>45</sup> ↓ <sup>49</sup> ↓ <sup>57</sup> •46,78,53	•156	—
HLA	Baseline	•50	•41,44,68,58	•50,58,39	•41,44	•41,44,68,58	•41,68	—	↑ <sup>40</sup> •60,39	•69,61	•69
	Slope	—	•41,44	—	•41,44	•41,44	•41	—	↑ <sup>45</sup> —	—	—

Fig. 1. Reported gene – cognitive domain associations.

Gene	Metric	Cognitive Domain									
		AT	EM	EF	VA	PS	WM	VS	GC	GF	BC
PT2KB	Baseline	.50	.41, .44, .68, .58, .56	.50, .58, .39	.41, .44	.41, .44, .68, .58, .39	.41, .68	—	.40, .38, .60, .39	.69, .61	.69
	Slope	—	.41, .44	—	.41, .44	.41, .44	.41	—	‡45	—	—
SLC24A4	Baseline	.50	.41, .44, .68, .58, .56	.50, .58, .39	.41, .44	.41, .44, .68, .58, .39	.41, .68	—	.40, .38, .60, .39	.69, .61	.69
	Slope	—	.41, .44	—	.41, .44	.41, .44	.41	—	‡45	—	—
SORL1	Baseline	.50	.41, .44, .68, .58, .56, .91, .63	.50, .58, .60, .63, .39	.41, .44, .91, .62, .63	.41, .68, .58, .91, .62, .66, .39	.41, .68, .91, .62	.91, .62, .64, .63	.65, ‡40	.69, .61	.69
	Slope	—	.41, .44, .88	‡66	.41, .44	.41, .44, .66	.41	‡66	‡45, ‡59	—	—
INPP5D	Baseline	—	.41, .44, .68, .58, .56	.58, .39	.41	.41, .44, .68, .58, .39	.41, .68	—	.40, .38, .39	.69, .61	.69
	Slope	—	.41	—	.41, .44	.41	.41	—	‡59	—	—
IMEF2C	Baseline	.50	.41, .44, .58, .56	.50, .58	.41, .44	.41, .44, .58, .39	.41	—	.40, .38, .60, .39	.69, .61	.69
	Slope	—	.41, .44	—	.41, .44	.41, .44	.41	—	‡45	—	—
NME8	Baseline	.50	.41, .44, .68, .58, .67	.50, .39	.41, .44	.41, .44, .68, .39	.41, .68	—	.40, .38, .60, .39	.61	—
	Slope	—	.41, .44, .67	—	.41	.41, .44	.41	—	‡67	—	—
ZCWPW1	Baseline	.50	.41, .44, .68, .58, .56	.50, .58, .39	.41, .44	.41, .44, .68, .58, .39	.41, .68	—	.40, .38, .60, .39	.69, .61	.69
	Slope	—	.41	—	.41, .44	.41, .44	.41	—	.45	—	—
CELFI	Baseline	.50	.41, .58, .56	.58, .39, .50	.41, .44	.41, .58	.41	—	.40, .38, .60, .39	.61	—
	Slope	—	.41, .44	—	.41, .44	.41, .44	.41	—	‡45	—	—
FERMT2	Baseline	.50	.41, .44, .58, .56	.50, .58, .39	.41	.41, .44, .68, .58, .39	.41, .68	—	.40, .38, .60, .39	.69, .61	.69
	Slope	—	.41, .44	—	.41, .44	.41	.41	—	.45	—	—
CASS4	Baseline	.50	.41, .44, .68, .58, .56	.50, .58, .39	.41, .44	.41, .44, .68, .58, .39	.41, .68	—	.40, .38, .60, .39	.69, .61	.69
	Slope	—	.41, .44	—	.41, .44	.41, .44	.41	—	‡15, .45	—	—
HBEGF	Baseline	.50	—	.39, .50	—	.39	—	—	.40, .38, .60, .39	.69, .61	.69
	Slope	—	—	—	—	—	—	—	‡40, .38, .60, .39	.69, .61	.69

Fig. 1. (continued)

Gene	Metric	Cognitive Domain											
		AT	EM	EF	VA	PS	WM	VS	GC	GF	gC		
SPPL2A	Baseline	.50	—	↑ <sup>39</sup> •50	—	.39	—	—	?	?	?	.69	.69
	Baseline	.50	—	•39,50	—	.39	—	—	•40,38,60,39	—	—	.69	.69
	Baseline	.50	—	•39,50	—	.39	—	—	•40,38,60,39	—	—	.69	.69
ADAM10	Baseline	.50	—	•39,50	—	.39	—	—	↓ <sup>39</sup> •40,38,60	—	—	.69	.69
	Baseline	? <sup>50</sup>	—	? <sup>50</sup> 39	—	.39	—	—	•40,38,60,39	—	—	.69	.69
ACE	Baseline	.50	—	.39	—	? <sup>39</sup>	—	—	? <sup>40</sup> 38,60,39	—	—	.69	.69
	Baseline	? <sup>50</sup>	—	↑ <sup>39</sup> 50	—	.39	—	—	? <sup>38</sup> 40,60,39	—	—	.69	.69
TREM2	Baseline	.50	—	•39,50	—	.39	—	—	•40,38,60,39	—	—	.69	.69
	Baseline	.50	—	39,50	—	.39	—	—	•40,38,60,39	—	—	.69	.69
WWOX	Baseline	.50	—	39,50	—	↓ <sup>39</sup>	—	—	? <sup>40</sup> ,38,? <sup>39</sup> 60	—	—	.69	.69
	Baseline	.50	—	↓ <sup>39</sup> 50	—	↑ <sup>39</sup>	—	—	•40,38,60,39	—	—	.69	.69
ADAMTS4	Baseline	.50	—	39,50	—	.39	—	—	? <sup>40</sup> 38,60,39	—	—	.69	.69
	Baseline	.50	—	39,50	—	? <sup>39</sup>	—	—	•40,38,60,39	—	—	.69	.69
CLNK	Baseline	.50	—	↓ <sup>39</sup> 50	—	↑ <sup>39</sup>	—	—	? <sup>39</sup> 40,38,60	—	—	.69	.69
	Baseline	.50	—	39,50	—	.39	—	—	? <sup>38</sup> ,? <sup>39</sup> 40,60	—	—	.69	.69
APH1B	Baseline	.50	—	39,50	—	? <sup>39</sup>	—	—	•40,38,60,39	—	—	.69	.69
	Baseline	.50	—	39,50	—	↑ <sup>39</sup>	—	—	? <sup>60</sup> ,? <sup>39</sup> 40,38	—	—	.69	.69
ALPK2	Baseline	.50	—	39,50	—	.39	—	—	? <sup>40</sup> 38,60,39	—	—	.69	.69
	Baseline	—	—	39	—	↑ <sup>39</sup>	—	—	? <sup>60</sup> ,? <sup>39</sup> 40,38	—	—	.69	.69

↓ Significant negative association; ↑ Significant positive association; ? significant association; — direction not reported; • non-significant association

Fig. 1. (continued)

Analysis	Metric	Cognitive Domains										
		AT	EM	EF	VA	PS	WM	VS	GC	gF	gC	
Unweighted GRS	(w/o ApoE)	Baseline	—	? <sup>70</sup>	• <sub>70</sub>	• <sub>70</sub>	• <sub>70</sub>	—	—	—	—	—
		Slope	—	—	—	—	—	—	—	—	—	—
	(incl. ApoE)	Baseline	—	• <sub>41</sub> • <sub>44</sub>	—	• <sub>41</sub> • <sub>44</sub>	• <sub>41</sub> • <sub>44</sub>	• <sub>41</sub>	—	—	—	—
		Slope	—	• <sub>41</sub> • <sub>44</sub>	—	• <sub>41</sub> • <sub>44</sub>	• <sub>41</sub> • <sub>44</sub>	• <sub>41</sub>	—	—	—	—
Weighted GRS	(w/o ApoE)	Baseline	—	↓ <sub>56</sub> ↓ <sub>48</sub> • <sub>41</sub> • <sub>42</sub> • <sub>68</sub> • <sub>71</sub> • <sub>46</sub>	• <sub>48</sub>	• <sub>41</sub> • <sub>46</sub>	↑ <sub>68</sub> • <sub>41</sub> • <sub>48</sub> • <sub>46</sub>	• <sub>41</sub> • <sub>68</sub>	—	↓ <sub>46</sub> • <sub>48</sub>	—	—
		Slope	—	↓ <sub>71</sub> • <sub>41</sub> • <sub>42</sub> • <sub>46</sub>	—	• <sub>41</sub> • <sub>46</sub>	• <sub>41</sub> • <sub>46</sub>	• <sub>41</sub>	—	• <sub>46</sub> • <sub>78</sub>	—	—
	(incl. ApoE)	Baseline	—	↓ <sub>42</sub> ↓ <sub>56</sub> ↓ <sub>71</sub> ↓ <sub>48</sub> • <sub>41</sub> • <sub>68</sub> • <sub>46</sub>	↓ <sub>48</sub>	↓ <sub>46</sub> • <sub>41</sub>	↓ <sub>46</sub> • <sub>41</sub> • <sub>68</sub> • <sub>48</sub>	• <sub>41</sub> • <sub>68</sub>	—	↓ <sub>48</sub> ↓ <sub>46</sub>	—	—
		Slope	—	↓ <sub>41</sub> ↓ <sub>42</sub> ↓ <sub>71</sub> ↓ <sub>46</sub>	—	↓ <sub>46</sub> • <sub>41</sub>	↓ <sub>41</sub> • <sub>46</sub>	• <sub>41</sub>	—	↓ <sub>46</sub>	—	—
PGRS	Baseline	• <sub>73</sub>	↓ <sub>72</sub> ↓ <sub>74</sub> ↓ <sub>73</sub> ↓ <sub>95</sub> • <sub>96</sub> •	↓ <sub>95</sub> • <sub>72</sub> •	—	• <sub>74</sub> • <sub>96</sub>	—	—	↓ <sub>73</sub> • <sub>96</sub>	• <sub>96</sub>	• <sub>96</sub>	
	Slope	—	↓ <sub>72</sub> ↓ <sub>75</sub>	↓ <sub>72</sub> ↓ <sub>75</sub>	—	—	—	—	? <sub>73</sub> • <sub>96</sub>	—	—	

↓ Significant negative association; ↓ Significant positive association; ? significant association; — direction not reported; • non-significant association

Fig. 2. Reported genetic risk scores – cognitive domain associations.

rs3865444 were associated with change in GC in females [45].

### CLU

rs11136000(C) was associated with faster decline in WM [41] and EM in participants who converted to MCI/AD, but not in participants who remained cognitively normal [51]. rs11136000(C) was also associated with better performance in EM in a combined cohort of case/controls, but not in non-demented subjects only [52]. In a follow-up study, rs11136000(G) was associated with worse baseline performance in EM [42]. rs11136000(T) minor allele was associated faster decline in GC [53]. Mengel-From et al. [54, 55] investigated the association of four separate SNPs in the CLU locus with cognitive function. They reported that rs11136000(T) was associated with better baseline GC, rs9331888(G) and rs9331908(T) were associated with slower decline and rs11136000(T) and rs1532278(T) were associated with faster decline [54, 55]. Bressler et al. [44] observed that rs9331896(C) was associated with better baseline performance in EM and a reduced rate of decline in PS. rs2279590(A) was associated with worse performance in EM [56] and two separate 3-SNP haplotypes were significantly associated with baseline performance in EM and VA [47].

### CRI

rs3818361(T) was associated with faster decline in AT [53], while rs3818361(A) was associated with baseline performance in GC and faster decline in VA [47, 46]. Additionally, in African-Americans rs3818361(A) was associated with worse performance in EM in both a combined case/control cohort and non-demented control only subjects [52]. rs6656401(A) was associated with improved baseline performance in PS in African-American [44] and with faster decline in EM, semantic memory, PS, VS, and GC [47, 57]. Finally, a 3-SNP haplotype and 2-SNP haplotype was associated with VA and GC, respectively [47]. The CRI gene region was associated with change in GC in females [45], PS [39], and GC [38].

### EPHA1

rs11767557(C) and rs11767557(T) were associated with worse EM performance [48] and faster decline in WM, respectively [41]. Additionally, rs11767557(A) was associated with a faster rate of decline in EM in participants who converted to

MCI/AD, but not in participants who remained cognitively normal [42].

### MS4A

MS4A6A-rs983392(G) was associated with worse EM performance [58] and in African-Americans with change in GC [59]. MS4A4E-rs670139(T) was associated with better baseline WM [41] and slower decline in EM [44]. The MS4A4E and MS4A6A gene regions were associated with GC [60].

### PICALM

rs3851179(A) and rs3851179(G) were associated with better baseline GC [54] and faster decline in GC respectively [49]. rs7110631(G) was associated with faster decline in EM, VA, and GC [57], while rs541458(C) was associated with an earlier age at midpoint in decline in a non-linear trajectory of GC [53]. In univariate analysis 4 SNPs (rs10501604, rs10792821, rs11234532, rs10501608) were associated with EF, while in haplotype analyses 12 3-SNP windows were associated with EF [47]. The PICALM gene region was associated with Gf performance [61] GC in a multi-trait analysis of intelligence and educational attainment [40], and with change in GC in males [45].

### SORL1

rs3824968(A) was associated with worse EM performance at age 70, before and after adjusting for childhood IQ at age 11 [62]. In Chinese participants, rs2070045(T) was associated with PS performance [63] and rs1699102(T) was associated with faster decline in EM and PS [64]. rs11218343(T) was associated with worse PS at baseline [41]. In African-Americans, rs11218343(C) was associated with change in GC [59]. The SOLRI gene region was associated with change in GC in males [45] and with GC in a multi-trait analysis of intelligence and educational attainment [40]. In a Dutch population-based study, rs668387(T), rs689021(A), and rs641120(T) were associated with worse EM performance, but better EM and GC performance [65]. A further three SNPs (rs3824968(T), rs2282649(T), rs1010159(C)) were associated with better performance in EF in the family based study [65]. In three Swedish based population cohorts, five SNPs (rs11600875, rs753780, rs7105365, rs11820794, rs2070045) were variously associated with performance in EM, VA, and VS [66].

The HLA gene region was associated with change in GC in a female only and male only cohort

[45]. The *PTK2B* gene region was associated with change in GC in males [45]. The *SLC24A4* gene region was associated with Gf performance [61] GC in a multi-trait analysis of intelligence and educational attainment [40] and in a meta-analysis inclusive of the UKBB [38], and change in GC [45]. *INPP5D*-rs35349669(T) was associated with better baseline VA [44], slower decline in EM, and faster decline in PS [41]. In African-Americans, the *INPP5D*-rs4585024(A) minor allele was associated with change in GC [59]. *MEF2C*-rs190982(A) was associated with decreased EF performance in the UKBB, though it was non-significant in an earlier, smaller, analysis [39]. The *MEF2C* gene region was associated with GC in a multi-trait analysis of intelligence and educational attainment [40], GC in two large meta-analyses inclusive of the UK Biobank [38], Gf performance [61], and change in GC in males [45]. *NME8*-rs12155159(G) was associated with slower decline in VA [44] and *NME8*-rs2718058(G) was associated with worse baseline performance and faster decline in GC [67]. *ZCWPW1*-rs1476679(T) was associated with slower decline in PS [41], while in African-Americans *ZCWPW1*-rs1476679(C) was associated with faster decline in EM [44]. For *CELFI*, rs6485758(A) was associated with better baseline performance in EM, VA, and PS [44], while rs10838725(C) and rs7933019(C) were associated with better baseline EF performance [58] and a slower decline in EM [41], respectively. rs10838725(T) was associated with decreased EF performance [39]. The *CELFI* gene region was associated with change in GC in females [45], GC in a multi-trait analysis of intelligence and educational attainment [40], GC in three large meta-analyses inclusive of the UK Biobank [38, 39], and with PS [39]. *FERMT2*-rs17125944(C) with better EM performance [68], worse baseline VA [44], and accelerated decline in PS [41]. *CASS4*-rs927174(C) was associated with change in GC in African-Americans [59].

For the novel loci identified by Yiu et al., Marionni et al., Janssen et al. and Kunkle et al., there were no articles that reported associations of these loci with cognitive performance. Our initial search identified 6 GWAS where summary statistics were publicly available and for which we could extract the reported associations. The *HBEGF* and *SPPL2A* gene regions were associated with GC in a multi-trait analysis of intelligence and educational attainment [40], and in two large meta-analyses inclusive of the UK Biobank [38,39]. The *ADAM10* gene region was associated

with GC and *ADAM10*-rs889555(T) was associated with worse GC performance [39]. The *KAT8* gene region was associated with AT and EF [50]. The *ACE* gene region was associated with EF [50], PS [39] performance in the UK Biobank, and GC [40]. The *CLNK* gene region was associated with PS and GC, while *CLNK*-rs6448453(A) was associated with worse and better EF and PS performance, respectively [39]. The *CNTNAP2* gene region was associated with GC in two large meta-analyses inclusive of the UK Biobank [38, 39] and general fluid intelligence [69]. The *APH1B* and *HESX1* gene regions were associated with PS in the UK Biobank [39]. The *ALPK2* and *ADAMTS4* gene regions were associated with GC in a multi-trait analysis of intelligence and educational attainment [40]. *ADAMTS1*-rs2830500(A) was associated with worse EF and better PS [39]. The *ABI3* gene region was associated with GC [39, 60] and gF [69] while *ABI3*-rs28394864(A) was associated with better PS. The *ACO74212.3* gene region was associated with GC and *ACO74212.3*-rs76320948(T) was associated with worse GC [39, 60] and better PS [39]. The *OARD1* gene region was associated with AT [50] and GC [38], while rs114812713(C) was associated with better PS [39]. *IQCK*-rs7185636(T) was associated with worse GC performance [39]. The *WWOX* gene region was associated with GC [38–40] while *WWOX*-rs62039712(A) was associated with worse PS [39].

#### Association of AD GRS with cognitive performance

We found 14 studies that investigated the cumulative effect of AD risk loci on cognitive performance. Three studies investigated the effect of an unweighted GRS on cognitive performance. An unweighted GRS composed of *PICALM*, *BINI*, and *CLU*, was associated with reduced EM performance [70]. In contrast, an unweighted GRS composed of the IGAP risk loci was not associated with either both cognitive performance or cognitive decline [38, 41]. Weighted GRSs that include *APOE* have shown more consistent results. GRS composed of SNPs identified in the initial GWAS have been associated with worse cognitive performance in EM [42, 46, 48], EF [48], VA [46], PS [46, 48], and GC [46, 48]. Studies that have used a GRS including the IGAP LOAD risk loci have also reported associations with worse performance in EM [41, 56, 71] and PS [41]. However, these associations largely reflect the effect of *APOE* as the majority are not statistically significant after the exclusion of

529 *APOE*. Pathway specific risk scores for A $\beta$  clearance,  
530 cholesterol metabolism, and immune response were  
531 also constructed but were non-significant [68].

532 Five studies have utilized a GRS approach,  
533 whereby a GRS is calculated based on all genome-  
534 wide significant SNPs, plus all nominally associated  
535 variants at a given significance level ( $P_T$ ). Two GRS  
536 ( $P_T = 0.01$ ) were associated with worse baseline EM  
537 and faster decline on EF and [72] and with worse EM  
538 and GC and faster decline in GC [73]. A third GRS  
539 composed of all LOAD-related SNPs ( $P_T = 1$ ) except  
540 for those within 500 kb of *APOE* was associated with  
541 worse baseline EM [74]. One study found that GRS  
542 across a range  $P_T$  ranging from  $1e-7$  to  $1e-2$  was asso-  
543 ciated with faster EM and EF performance decline in  
544 A $\beta$ +, but not A $\beta$ - individuals [75].

## 545 DISCUSSION

546 This is the first systematic review to evaluate the  
547 role of non-*APOE* LOAD GWAS risk loci in cogni-  
548 tive decline. Based on a synthesis of data from 49  
549 published studies, the results between individual risk  
550 loci and specific cognitive domains were largely non-  
551 significant for both baseline/cross-sectional cognitive  
552 performance and for longitudinal cognitive change.  
553 Of the significant gene-cross-sectional/longitudinal  
554 cognition associations that were reported ( $n = 128$ ),  
555 the majority ( $n = 96$ ) were not reproduced; other  
556 reviewed studies reported non-significant associa-  
557 tions. Moreover, inconclusive patterns emerged for  
558 significant associations that were reproduced by one  
559 or more studies. Specifically, three reported signif-  
560 icant effects in the same direction, three reported  
561 significant associations, but with inconsistent direc-  
562 tions of effect, 12 were reproduced as significant by  
563 studies that did not report the direction of effect, and  
564 finally, 12 were reported as significant but no direc-  
565 tion of effect was reported. However, it should be  
566 noted, where significant associations were reported  
567 and reproduced, the majority of further replication  
568 studies reported non-significant associations results.  
569 Overall, global cognition was the most extensively  
570 examined cognitive domain, with 77/255 significant  
571 associations reported. This low rate of significance  
572 and the concomitant lack of reproducibility of sig-  
573 nificant associations were observed across all the  
574 cognitive domains.

575 In contrast to univariate and gene-based analysis,  
576 we found more studies reporting consistent signif-  
577 icant results of genetic risk scores associated with

578 episodic memory performance. GRS composed of  
579 GWAS top hits and *APOE* were associated with  
580 worse cognitive performance in episodic memory,  
581 with 4/7 cross-sectional studies and 4/4 longitudinal  
582 studies reporting significant associations. However,  
583 these effects were largely driven by *APOE*, with  
584 only 2/7 baseline associations and 1/4 longitudi-  
585 nal associations retaining significance after *APOE*  
586 was excluded from the GRS. GRS composed of  
587 all nominally associated variants at a given signif-  
588 icance level were also consistently associated with  
589 worse episodic memory performance, with 5/6  
590 of the studies reporting significant associations. Given  
591 these results, future studies should focus on the use  
592 of GRS rather than individual variants, where the  
593 effects are likely too small to be reliably detected  
594 in a univariate analysis [76]. Furthermore, aggre-  
595 gating risk variants based on biological function  
596 may offer a more powerful approach to evaluat-  
597 ing the association of genetic variants with specific  
598 endophenotypes [68].

### 599 Sample size/statistical power

600 A major limitation of the reported studies is small  
601 sample sizes and consequently low statistical power.  
602 In order to detect a genetic variant explaining 1%  
603 of cognitive variance at 80% power, early analy-  
604 ses suggested a sample size of 800–1,000 [77], but  
605 more recent genome-wide associations analyses esti-  
606 mate 10,000–15 000 is required [78]. Of the included  
607 studies, 37/49 had a sample size greater than 1,000,  
608 but only 9/49 studies had greater than 10,000. The  
609 two largest GWAS of cognitive performance to date,  
610 conducted as a meta-analysis of the UK Biobank  
611 and other consortia ( $n = 300,486$  [39] &  $n = 269,867$   
612 [38]), found three LOAD gene-regions reaching  
613 genome-wide significance: *MEF2C*, *HBEGF*, and  
614 *SPPL2A*. However, it should be noted that *HBEGF*  
615 and *SPPL2A* were associated with dementia proxy  
616 case/control status in the UK Biobank and in both  
617 of these studies the majority of the samples (~30%)  
618 originated in the UKBB. The UK Biobank has two  
619 limitations relevant to this review: it is limited to a  
620 cross-sectional design and the cognitive assessments  
621 used are brief non-standard tests that are suscep-  
622 tible to floor/ceiling effects [79]. Future studies,  
623 particularly longitudinal studies, should recruit larger  
624 sample sizes, or alternately, greater efforts should be  
625 made to harmonize data across studies to facilitate  
626 meta-analysis.

### 627 Phenotypic heterogeneity

628 Phenotypic heterogeneity between studies due to  
629 the use of different cognitive tests can limit repli-  
630 cation [61]. While cognitive test results are highly  
631 correlated, some tests may lack the sensitivity to  
632 identify associations with small effect sizes, such  
633 as Mini-Mental State Examination (MMSE) [80],  
634 a commonly used GC test. MMSE was designed  
635 as a screening test for dementia and not a mea-  
636 sure of cognitive abilities. It therefore exhibits strong  
637 ceiling effects, limiting its ability to differentiate  
638 between medium and high cognitive performers [81].  
639 There was vast between-study variability in the spe-  
640 cific measures used to assess the different cognitive  
641 domains. Although most of the cognitive measures  
642 used were psychometrically sound, replication of  
643 genetic effects on a specific cognitive domain may  
644 have been tested using measures that differed in valid-  
645 ity, reliability, or sensitivity [82]. Additionally, when  
646 evaluating the effects of AD risk loci on cognitive  
647 aging a broad range of relevant cognitive domains  
648 should be assessed using multiple cognitive tests  
649 per domain. The construction of latent variables or  
650 composite scores offer several advantages over using  
651 single cognitive tests scores [83]. For example, latent  
652 variables use multiple indicators, rather than a single  
653 measure, thus representing a more compressive cog-  
654 nitive construct that by design reduces the impact of  
655 varying psychometric properties [84]. Alternatively,  
656 when examining cognition as an endophenotype of  
657 LOAD, a cognitive test battery focused on cognitive  
658 domains more directly affected pre-clinical AD, such  
659 as episodic memory, may be warranted. Given these  
660 findings, future studies should 1) focus on specific  
661 cognitive domains rather than global tests; 2) choose  
662 cognitive tests specifically for their sensitivity to mea-  
663 sure subtle cognitive differences; 3) use multiple tests  
664 to assess cognitive function of a single domain; and  
665 4) that are robust to test-retest effects.

### 666 Sample characteristics

667 Variation in sample characteristics such as age, sex,  
668 education, ethnicity, and medical comorbidities can  
669 limit replicability. In particular, inclusion/exclusion  
670 of individuals who develop dementia during a study  
671 may affect results. Of the studies included in this  
672 review, 26/49 were conducted in non-demented pop-  
673 ulations, 11/49 included participants with prevalent  
674 or incident dementia, while 12/49 studies did not  
675 report the cognitive status of its participants. The

676 reported associations of LOAD risk loci in pop-  
677 ulations that retain prevalent or incident cases of  
678 cognitive impairment may be driven by pathologi-  
679 cal cognitive decline [61, 85]. In contrast, in studies  
680 that selectively exclude participants with a clinical  
681 diagnosis of dementia, the inadvertent inclusion of  
682 individuals in prodromal stages of dementia may  
683 also drive the reported genetic effects [85]. Evi-  
684 dence to suggest this effect has been reported in  
685 studies that separately assessed associations in par-  
686 ticipants who eventually converted to dementia and  
687 those who remained cognitively normal for *ABCA7*,  
688 *EPHA1*, and *CLU* [42, 51]. Similar effects have been  
689 observed for *APOE\*ε4* carriers [85]. In cognitively  
690 normal *APOE\*ε4* carriers, participants with a high  
691 Aβ PET levels experienced a faster rate of decline  
692 then carriers with low Aβ PET levels, suggesting  
693 that cognitive decline observed in *APOE\*ε4* carriers  
694 reflects the effect of *APOE* exacerbating Aβ-related  
695 decline rather than an *APOE*-independent effect [86].  
696 Accordingly, future studies should evaluate the asso-  
697 ciation of LOAD risk loci with cognitive function  
698 using neuroimaging or cerebrospinal fluid biomark-  
699 ers to inform the classification of preclinical AD in  
700 'cognitively normal' individuals. Furthermore, sen-  
701 sitivity analysis should be conducted to evaluate if  
702 the inclusion/exclusion of participants with MCI or  
703 dementia drives potential association of genetic vari-  
704 ants on cognitive function.

### 705 Limitations

706 There are several limitations to this review. First,  
707 the heterogeneity in the methodologies (cognitive  
708 tests, genetic polymorphisms, and study design) of  
709 the included studies precluded performing a meta-  
710 analysis, which would offer increased power to detect  
711 associations and increased precision in the estimation  
712 of the magnitude of the effect. Second, we empha-  
713 size that we have reported significant associations  
714 that were  $p < 0.05$  but as such the number of 'true'  
715 associations is probably smaller than the number  
716 reported here due to multiple testing and undetected  
717 publication bias. Third, the literature search used a  
718 single database, PubMed, which could limit the sen-  
719 sitivity of our search strategy. However, PubMed is  
720 by far the most populated database for publications  
721 for general medical and biomedical science offering  
722 a higher likelihood of retrieval of relevant publica-  
723 tions. In addition, we followed up reference lists  
724 for all included studies and this retrieved less than  
725 5% of studies eventually included, suggesting an

726 acceptable sensitivity for the bibliographic database  
727 searches. Finally, while we adapted our search strat-  
728 egy from a published filter for detecting causation  
729 studies that favored sensitivity, it is possible that  
730 not all relevant studies were identified as our search  
731 strategy relied on the gene names or SNP identi-  
732 fiers being present within the title or abstract of a  
733 publication.

### 734 Conclusion

735 This is the first study to systematically evaluate  
736 the role of non-*APOE* LOAD risk loci with cog-  
737 nitive performance and decline. We found that the  
738 majority of associations between individual LOAD  
739 risk loci and cognitive function were non-significant,  
740 suggesting that current samples sizes are too small  
741 to detect individual risk loci effects on cognition. In  
742 contrast, consistent findings were observed for GRS,  
743 with increased LOAD genetic risk associated with  
744 deleterious effects on episodic memory performance  
745 and decline. Future research should focus on the use  
746 of GRS, recruitment of larger sample sizes or har-  
747 monization of findings across studies, and improved  
748 phenotyping of cognitive abilities. Consideration of  
749 these factors in future study design may allow for  
750 more reliable associations of LOAD-related genetic  
751 variants with ageing-related cognitive performance  
752 and change.

### 753 ACKNOWLEDGMENTS

754 SJA is funded by the Australian Research Council  
755 Centre of Excellence in Population Ageing Research,  
756 ARC grant CE1101029. KJA is funded by NHMRC  
757 Research Fellowship No. 1002560. RAD acknowl-  
758 edges funding from the National Institutes of Health  
759 (National Institute on Aging, R01 AG008235) and  
760 the Canadian Consortium on Neurodegeneration in  
761 Aging (with funding from the Canadian Institutes of  
762 Health Research and partners).

763 Authors' disclosures available online ([https://](https://www.j-alz.com/manuscript-disclosures/19-0342)  
764 [www.j-alz.com/manuscript-disclosures/19-0342](https://www.j-alz.com/manuscript-disclosures/19-0342)).

### 765 SUPPLEMENTARY MATERIAL

766 The supplementary material is available in the  
767 electronic version of this article: [http://dx.doi.org/](http://dx.doi.org/10.3233/JAD-190342)  
768 [10.3233/JAD-190342](http://dx.doi.org/10.3233/JAD-190342).

### REFERENCES

- 769
- [1] Salthouse TA (2009) When does age-related cognitive decline begin? *Neurobiol Aging* **30**, 507-514. 770 771
  - [2] Josefsson M, de Luna X, Pudas S, Nilsson L-G, Nyberg L (2012) Genetic and lifestyle predictors of 15-year longitudinal change in episodic memory. *J Am Geriatr Soc* **60**, 2308-2312. 772 773 774 775
  - [3] Salthouse TA (2009) Decomposing age correlations on neuropsychological and cognitive variables. *J Int Neuropsychol Soc* **15**, 650-661. 776 777 778
  - [4] Liverman CT, Yaffe K, Blazer DG (2015) *Cognitive aging: Progress in understanding and opportunities for action*, National Academies Press. 779 780 781
  - [5] Qiu C, Fratiglioni L (2015) A major role for cardiovascular burden in age-related cognitive decline. *Nat Rev Cardiol* **12**, 267-277. 782 783 784
  - [6] Feinkohl I, Price JF, Strachan MW, Frier BM (2015) The impact of diabetes on cognitive decline: Potential vascular, metabolic, and psychosocial risk factors. *Alzheimers Res Ther* **7**, 46. 785 786 787 788
  - [7] Lucin KM, Wyss-Coray T (2009) Immune activation in brain aging and neurodegeneration: Too much or too little? *Neuron* **64**, 110-122. 789 790 791
  - [8] Masters CL, Bateman R, Blennow K, Rowe CC, Sperling RA, Cummings JL (2015) Alzheimer's disease. *Nat Rev Dis Primers* **1**, 15056. 792 793 794
  - [9] Braak H, Thal DR, Ghebremedhin E, Del Tredici K (2011) Stages of the pathologic process in Alzheimer disease: Age categories from 1 to 100 years. *J Neuropathol Exp Neurol* **70**, 960-969. 795 796 797 798
  - [10] Jansen WJ, Ossenkopppele R, Knol DL, Tijms BM, Scheltens P, Verhey FRJ, Visser PJ, Aalten P, Aarsland D, Alcolea D, Alexander M, Almdahl IS, Arnold SE, Baldeiras I, Barthel H, van Berckel BNM, Bibeau K, Blennow K, Brooks DJ, van Buchem MA, Camus V, Cavedo E, Chen K, Chetelat G, Cohen AD, Drzezga A, Engelborghs S, Fagan AM, Fladby T, Fleisher AS, van der Flier WM, Ford L, Forster S, Fortea J, Foskett N, Frederiksen KS, Freund-Levi Y, Frisoni GB, Froelich L, Gabryelewicz T, Gill KD, Gkatzima O, Gomez-Tortosa E, Gordon MF, Grimmer T, Hampel H, Hausner L, Hellwig S, Herukka S-K, Hildebrandt H, Ishihara L, Ivanoiu A, Jagust WJ, Johannsen P, Kandimalla R, Kapaki E, Klimkiewicz-Mrowiec A, Klunk WE, Kohler S, Koglin N, Kornhuber J, Kramerberger MG, Van Laere K, Landau SM, Lee DY, de Leon M, Lisetti V, Lleo A, Madsen K, Maier W, Marcusson J, Mattsson N, de Mendonca A, Meulenbroek O, Meyer PT, Mintun MA, Mok V, Molinuevo JL, Mollergard HM, Morris JC, Mroczko B, Van der Mussele S, Na DL, Newberg A, Nordberg A, Nordlund A, Novak GP, Paraskevas GP, Parnetti L, Perera G, Peters O, Popp J, Prabhakar S, Rabinovici GD, Ramakers IHGB, Rami L, Resende de Oliveira C, Rinne JO, Rodrigue KM, Rodriguez-Rodriguez E, Roe CM, Rot U, Rowe CC, Ruther E, Sabri O, Sanchez-Juan P, Santana I, Sarazin M, Schroder J, Schutte C, Seo SW, Soetewey F, Soininen H, Spuru L, Struyfs H, Teunissen CE, Tsolaki M, Vandenberghe R, Verbeek MM, Villemagne VL, Vos SJB, van Waalwijk van Doorn LJC, Waldemar G, Wallin A, Wallin AK, Wiltfang J, Wolk DA, Zboch M, Zetterberg H (2015) Prevalence of cerebral amyloid pathology in persons without dementia: A meta-analysis. *JAMA* **313**, 1924-1938. 799 800 801 802 803 804 805 806 807 808 809 810 811 812 813 814 815 816 817 818 819 820 821 822 823 824 825 826 827 828 829
  - [11] Scholl M, Lockhart SN, Schonhaut DR, O'Neil JP, Janabi M, Ossenkopppele R, Baker SL, Vogel JW, Faria J, Schwimmer HD, Rabinovici GD, Jagust WJ (2016) PET imaging 830 831 832

- of tau deposition in the aging human brain. *Neuron* **89**, 971-982.
- [12] Johnson KA, Schultz A, Betensky RA, Becker JA, Sepulcre J, Rentz D, Mormino E, Chhatwal J, Amariglio R, Papp K, Marshall G, Albers M, Mauro S, Pepin L, Alverio J, Judge K, Philiossaint M, Shoup T, Yokell D, Dickerson B, Gomez-Isla T, Hyman B, Vasdev N, Sperling R (2016) Tau positron emission tomographic imaging in aging and early Alzheimer disease. *Ann Neurol* **79**, 110-119.
- [13] Hedden T, Oh H, Younger AP, Patel TA (2013) Meta-analysis of amyloid-cognition relations in cognitively normal older adults. *Neurology* **80**, 1341-1348.
- [14] Boyle PA, Yu L, Wilson RS, Schneider JA, Bennett DA (2013) Relation of neuropathology with cognitive decline among older persons without dementia. *Front Aging Neurosci* **5**, 50.
- [15] Petersen RC, Wiste HJ, Weigand SD, Rocca WA, Roberts RO, Mielke MM, Lowe VJ, Knopman DS, Pankratz VS, Machulda MM, Geda YE, Jack CR Jr (2016) Association of elevated amyloid levels with cognition and biomarkers in cognitively normal people from the community. *JAMA Neurol* **73**, 85-92.
- [16] Hassenstab J, Chasse R, Grabow P, Benzinger TLS, Fagan AM, Xiong C, Jasielec M, Grant E, Morris JC (2016) Certified normal: Alzheimer's disease biomarkers and normative estimates of cognitive functioning. *Neurobiol Aging* **43**, 23-33.
- [17] Yu L, Boyle PA, Leurgans S, Schneider JA, Bennett DA (2014) Disentangling the effects of age and APOE on neuropathology and late life cognitive decline. *Neurobiol Aging* **35**, 819-826.
- [18] Hohman TJ, Tommet D, Marks S, Contreras J, Jones R, Mungas D, Alzheimer's Neuroimaging Initiative (2017) Evaluating Alzheimer disease biomarkers as mediators of age-related cognitive decline. *Neurobiol Aging* **58**, 120-128.
- [19] Ridge PG, Hoyt KB, Boehme K, Mukherjee S, Crane PK, Haines JL, Mayeux R, Farrer LA, Pericak-Vance MA, Schellenberg GD, Kauwe JSK (2016) Assessment of the genetic variance of late-onset Alzheimer's disease. *Neurobiol Aging* **41**, 200.e13-20.
- [20] Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, Roses AD, Haines JL, Pericak-Vance MA (1993) Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. *Science* **261**, 921-923.
- [21] Harold D, Abraham R, Hollingworth P, Sims R, Gerrish A, Hamshere ML, Pahwa JS, Moskvina V, Dowzell K, Williams A, Jones N, Thomas C, Stretton A, Morgan AR, Lovestone S, Powell J, Proitsi P, Lupton MK, Brayne C, Rubinsztein DC, Gill M, Lawlor B, Lynch A, Morgan K, Brown KS, Passmore PA, Craig D, McGuinness B, Todd S, Holmes C, Mann D, Smith AD, Love S, Kehoe PG, Hardy J, Mead S, Fox N, Rossor M, Collinge J, Maier W, Jessen F, Schurmann B, van den Bussche H, Heuser I, Kornhuber J, Wiltfang J, Dichgans M, Frolich L, Hampel H, Hull M, Rujescu D, Goate AM, Kauwe JSK, Cruchaga C, Nowotny P, Morris JC, Mayo K, Sleegers K, Bettens K, Engelborghs S, De yn PP, Van Broeckhoven C, Livingston G, Bass NJ, Gurling H, McQuillin A, Gwilliam R, Deloukas P, Al-Chalabi A, Shaw CE, Tsolaki M, Singleton AB, Guerreiro R, Muhleisen TW, Nothen MM, Moebus S, Jockel K-H, Klopp N, Wichmann HE, Carrasquillo MM, Pankratz VS, Younkin SG, Holmans PA, O'Donovan M, Owen MJ, Williams J (2009) Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. *Nat Genet* **41**, 1088-1093.
- [22] Hollingworth P, Harold D, Sims R, Gerrish A, Lambert J-C, Carrasquillo MM, Abraham R, Hamshere ML, Pahwa JS, Moskvina V, Dowzell K, Jones N, Stretton A, Thomas C, Richards A, Ivanov D, Widdowson C, Chapman J, Lovestone S, Powell J, Proitsi P, Lupton MK, Brayne C, Rubinsztein DC, Gill M, Lawlor B, Lynch A, Brown KS, Passmore PA, Craig D, McGuinness B, Todd S, Holmes C, Mann D, Smith AD, Beaumont H, Warden D, Wilcock G, Love S, Kehoe PG, Hooper NM, Vardy ERLC, Hardy J, Mead S, Fox NC, Rossor M, Collinge J, Maier W, Jessen F, Ruther E, Schurmann B, Heun R, Kolsch H, van den Bussche H, Heuser I, Kornhuber J, Wiltfang J, Dichgans M, Frolich L, Hampel H, Gallacher J, Hull M, Rujescu D, Giegling I, Goate AM, Kauwe JSK, Cruchaga C, Nowotny P, Morris JC, Mayo K, Sleegers K, Bettens K, Engelborghs S, De yn PP, Van Broeckhoven C, Livingston G, Bass NJ, Gurling H, McQuillin A, Gwilliam R, Deloukas P, Al-Chalabi A, Shaw CE, Tsolaki M, Singleton AB, Guerreiro R, Muhleisen TW, Nothen MM, Moebus S, Jockel K-H, Klopp N, Wichmann HE, Pankratz VS, Sando SB, Aasly JO, Barcikowska M, Wszolek ZK, Dickson DW, Graff-Radford NR, Petersen RC, van Duijn CM, Breteler MMB, Ikram MA, DeStefano AL, Fitzpatrick AL, Lopez O, Launer LJ, Seshadri S, Berr C, Campion D, Epelbaum J, Dartigues J-F, Tzourio C, Alperovitch A, Lathrop M, Feulner TM, Friedrich P, Riehle C, Krawczak M, Schreiber S, Mayhaus M, Nicolhaus S, Wagenpfeil S, Steinberg S, Stefansson H, Stefansson K, Snaedal J, Bjornsson S, Jonsson PV, Chouraki V, Genier-Boley B, Hiltunen M, Soininen H, Combarros O, Zelenika D, Delepine M, Bullido MJ, Pasquier F, Mateo I, Frank-Garcia A, Porcellini E, Hanon O, Coto E, Alvarez V, Bosco P, Siciliano G, Mancuso M, Panza F, Solfrizzi V, Nacmias B, Sorbi S, Bossu P, Piccardi P, Arosio B, Annoni G, Seripa D, Pilotto A, Scarpini E, Galimberti D, Brice A, Hannequin D, Licastro F, Jones L, Holmans PA, Jonsson T, Riemenschneider M, Morgan K, Younkin SG, Owen MJ, O'Donovan M, Amouyel P, Williams J (2011) Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. *Nat Genet* **43**, 429-435.
- [23] Naj AC, Jun G, Beecham GW, Wang L-S, Vardarajan BN, Buros J, Gallins PJ, Buxbaum JD, Jarvik GP, Crane PK, Larson EB, Bird TD, Boeve BF, Graff-Radford NR, De Jager PL, Evans D, Schneider JA, Carrasquillo MM, Ertekin-Taner N, Younkin SG, Cruchaga C, Kauwe JSK, Nowotny P, Kramer P, Hardy J, Huentelman MJ, Myers AJ, Barmada MM, Demirci FY, Baldwin CT, Green RC, Rogava E, George-Hyslop PS, Arnold SE, Barber R, Beach T, Bigio EH, Bowen JD, Boxer A, Burke JR, Cairns NJ, Carlson CS, Carney RM, Carroll SL, Chui HC, Clark DG, Corneveaux J, Cotman CW, Cummings JL, DeCarli C, DeKosky ST, Diaz-Arrastia R, Dick M, Dickson DW, Ellis WG, Faber KM, Fallon KB, Farlow MR, Ferris S, Frosch MP, Galasko DR, Ganguli M, Gearing M, Geschwind DH, Ghetti B, Gilbert JR, Gilman S, Giordani B, Glass JD, Growdon JH, Hamilton RL, Harrell LE, Head E, Honig LS, Hulette CM, Hyman BT, Jicha GA, Jin L-W, Johnson N, Karlawish J, Karydas A, Kaye JA, Kim R, Koo EH, Kowall NW, Lah JJ, Levey AI, Lieberman AP, Lopez OL, Mack WJ, Marson DC, Martiniuk F, Mash DC, Masliah E, McCormick WC, McCurry SM, McDavid AN, McKee AC, Mesulam M, Miller BL, Miller CA, Miller JW, Parisi JE, Perl DP, Peskind E, Petersen RC, Poon WW, Quinn JF, Rajbhandary RA, Raskind M, Reisberg B, Ringman JM, Roberson ED,

- 963 Rosenberg RN, Sano M, Schneider LS, Seeley W, Shelanski  
964 ML, Slifer MA, Smith CD, Sonnen JA, Spina S, Stern RA,  
965 Tanzi RE, Trojanowski JQ, Troncoso JC, Van Deerlin VM,  
966 Vinters HV, Vonsattel JP, Weintraub S, Welsh-Bohmer KA,  
967 Williamson J, Woltjer JL, Cantwell LB, Dombroski BA,  
968 Beekly D, Lunetta KL, Martin ER, Kamboh MI, Saykin AJ,  
969 Reiman EM, Bennett DA, Morris JC, Montine TJ, Goate  
970 AM, Blacker D, Tsuang DW, Hakonarson H, Kukull WA,  
971 Foroud TM, Haines JL, Mayeux R, Pericak-Vance MA,  
972 Farrer LA, Schellenberg GD (2011) Common variants at  
973 MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associ-  
974 ated with late-onset Alzheimer's disease. *Nat Genet* **43**,  
975 436-441.
- [24] Seshadri S, Fitzpatrick AL, Ikram MA, DeStefano AL, Gud-  
976 nason V, Boada M, Bis JC, Smith AV, Carassquillo MM,  
977 Lambert J-C, Harold D, Schrijvers EMC, Ramirez-Lorca R,  
978 Debette S, Longstreth WT, Janssens ACJW, Pankratz VS,  
979 Dartigues J-F, Hollingworth P, Aspelund T, Hernández I,  
980 Beiser A, Kuller LH, Koudstaal PJ, Dickson DW, Tzourio  
981 C, Abraham R, Antunez C, Du Y, Rotter JJ, Aulchenko YS,  
982 Harris TB, Petersen RC, Berr C, Owen MJ, Lopez-Arrieta  
983 J, Varadarajan BN, Becker JT, Rivadeneira F, Nalls MA,  
984 Graff-Radford NR, Campion D, Auerbach S, Rice K, Hof-  
985 man A, Jonsson PV, Schmidt H, Lathrop M, Mosley TH, Au  
986 R, Psaty BM, Uitterlinden AG, Farrer LA, Lumley T, Ruiz  
987 A, Williams J, Amouyel P, Younkin SG, Wolf PA, Launer  
988 LJ, López OL, van Duijn CM, Breteler MMB, CHARGE  
989 Consortium, GERAD1 Consortium, EADI1 Consortium  
990 (2010) Genome-wide analysis of genetic loci associated  
991 with Alzheimer disease. *JAMA* **303**, 1832-1840.
- [25] Lambert J-C, Heath S, Even G, Campion D, Sleegers K,  
992 Hiltunen M, Combarros O, Zelenika D, Bullido MJ, Taver-  
993 nier B, Letenneur L, Bettens K, Berr C, Pasquier F, Fievet  
994 N, Barberger-Gateau P, Engelborghs S, De yn P, Mateo I,  
995 Franck A, Helisalmi S, Porcellini E, Hanon O, de Pancorbo  
996 MM, Lendon C, Dufouil C, Jaillard C, Leveillard T, Alvarez  
997 V, Bosco P, Mancuso M, Panza F, Nacmias B, Bossu P, Pic-  
998 cardì P, Annoni G, Seripa D, Galimberti D, Hannequin D,  
999 Licastro F, Soininen H, Ritchie K, Blanche H, Dartigues  
1000 J-F, Tzourio C, Gut I, Van Broeckhoven C, Alperovitch A,  
1001 Lathrop M, Amouyel P (2009) Genome-wide association  
1002 study identifies variants at CLU and CR1 associated with  
1003 Alzheimer's disease. *Nat Genet* **41**, 1094-1099.
- [26] Lambert JC, Ibrahim-Verbaas CA, Harold D, Naj AC, Sims  
1004 R, Bellenguez C, DeStefano AL, Bis JC, Beecham GW,  
1005 Grenier-Boley B, Russo G, Thornton-Wells TA, Jones N,  
1006 Smith AV, Chouraki V, Thomas C, Ikram MA, Zelenika D,  
1007 Vardarajan BN, Kamatani Y, Lin CF, Gerrish A, Schmidt  
1008 H, Kunkle B, Dunstan ML, Ruiz A, Bihoreau MT, Choi  
1009 SH, Reitz C, Pasquier F, Cruchaga C, Craig D, Amin N,  
1010 Berr C, Lopez OL, De Jager PL, Deramecourt V, Johnston  
1011 JA, Evans D, Lovestone S, Letenneur L, Moron FJ, Rubin-  
1012 sztein DC, Eiriksdottir G, Sleegers K, Goate AM, Fievet N,  
1013 Huentelman MW, Gill M, Brown K, Kamboh MI, Keller  
1014 L, Barberger-Gateau P, McGuinness B, Larson EB, Green R,  
1015 Myers AJ, Dufouil C, Todd S, Wallon D, Love S, Rogava  
1016 E, Gallacher J, St George-Hyslop P, Clarimon J, Lleo A,  
1017 Bayer A, Tsuang DW, Yu L, Tsolaki M, Bossu P, Spalletta  
1018 G, Proitsi P, Collinge J, Sorbi S, Sanchez-Garcia F, Fox NC,  
1019 Hardy J, Deniz Naranjo MC, Bosco P, Clarke R, Brayne C,  
1020 Galimberti D, Mancuso M, Matthews F, Moebus S, Mecocci  
1021 P, Del Zompo M, Maier W, Hampel H, Pilotto A, Bullido  
1022 M, Panza F, Caffarra P, Nacmias B, Gilbert JR, Mayhaus M,  
1023 Lannefelt L, Hakonarson H, Pichler S, Carrasquillo MM,  
1024 Ingelsson M, Beekly D, Alvarez V, Zou F, Valladares O,  
1025 Younkin SG, Coto E, Hamilton-Nelson KL, Gu W, Razquin  
1026 C, Pastor P, Mateo I, Owen MJ, Faber KM, Jonsson PV,  
1027 Combarros O, O'Donovan MC, Cantwell LB, Soininen H,  
1028 Blacker D, Mead S, Mosley THJ, Bennett DA, Harris TB,  
1029 Fratiglioni L, Holmes C, de Bruijn RF, Passmore P, Montine  
1030 TJ, Bettens K, Rotter JJ, Brice A, Morgan K, Foroud TM,  
1031 Kukull WA, Hannequin D, Powell JF, Nalls MA, Ritchie  
1032 K, Lunetta KL, Kauwe JS, Boerwinkle E, Riemenschneider  
1033 M, Boada M, Hiltunen M, Martin ER, Schmidt R, Rujescu  
1034 D, Wang LS, Dartigues JF, Mayeux R, Tzourio C, Hofman  
1035 A, Nothen MM, Graff C, Psaty BM, Jones L, Haines JL,  
1036 Holmans PA, Lathrop M, Pericak-Vance MA, Launer LJ,  
1037 Farrer LA, van Duijn CM, Van Broeckhoven C, Moskv-  
1038 ina V, Seshadri S, Williams J, Schellenberg GD, Amouyel  
1039 P (2013) Meta-analysis of 74,046 individuals identifies 11  
1040 new susceptibility loci for Alzheimer's disease. *Nat Genet*  
1041 **45**, 1452-1458.
- [27] Liu JZ, Erlich Y, Pickrell JK (2017) Case-control association  
1042 mapping by proxy using family history of disease. *Nat Genet*  
1043 **49**, 325-331.
- [28] Marioni RE, Harris SE, Zhang Q, McRae AF, Hagenaars  
1044 SP, Hill WD, Davies G, Ritchie CW, Gale CR, Starr JM,  
1045 Goate AM, Porteous DJ, Yang J, Evans KL, Deary IJ,  
1046 Wray NR, Visscher PM (2018) GWAS on family history  
1047 of Alzheimer's disease. *Transl Psychiatry* **8**, 99.
- [29] Jansen IE, Savage JE, Watanabe K, Bryois J, Williams DM,  
1048 Steinberg S, Sealock J, Karlsson IK, Hagg S, Athanasia  
1049 L, Voyle N, Proitsi P, Witoelar A, Stringer S, Aarsland D,  
1050 Almdahl IS, Andersen F, Bergh S, Bettella F, Bjornsson S,  
1051 Brækhus A, Bråthen G, de Leeuw C, Desikan RS, Djurovic  
1052 S, Dumitrescu L, Fladby T, Hohman TJ, Jonsson PV, Kid-  
1053 dle SJ, Rongve A, Saltvedt I, Sando SB, Selbæk G, Shoaib  
1054 M, Skene NG, Snaedal J, Stordal E, Ulstein ID, Wang Y,  
1055 White LR, Hardy J, Hjerling-Leffler J, Sullivan PF, van der  
1056 Flier WM, Dobson R, Davis LK, Stefansson H, Stefans-  
1057 son K, Pedersen NL, Ripke S, Andreassen OA, Posthuma D  
1058 (2019) Genome-wide meta-analysis identifies new loci and  
1059 functional pathways influencing Alzheimer's disease risk.  
1060 *Nat Genet* **51**, 404-413.
- [30] Kunkle BW, Grenier-Boley B, Sims R, Bis JC, Damotte V,  
1061 Naj AC, Boland A, Vronskaya M, van der Lee SJ, Amlie-  
1062 Wolf A, Bellenguez C, Frizatti A, Chouraki V, Martin ER,  
1063 Sleegers K, Badarinarayan N, Jakobsdottir J, Hamilton-  
1064 Nelson KL, Moreno-Grau S, Olsos R, Raybould R, Chen Y,  
1065 Kuzma AB, Hiltunen M, Morgan T, Ahmad S, Vardarajan  
1066 BN, Epelbaum J, Hoffmann P, Boada M, Beecham GW, Gar-  
1067 nier J-G, Harold D, Fitzpatrick AL, Valladares O, Moutet  
1068 M-L, Gerrish A, Smith AV, Qu L, Bacq D, Denning N,  
1069 Jian X, Zhao Y, del Zompo M, Fox NC, Choi S-H, Mateo  
1070 I, Hughes JT, Adams HH, Malamon J, Sanchez Garcia F,  
1071 Patel Y, Brody JA, Dombroski BA, Naranjo MCD, Dani-  
1072 ilidou M, Eiriksdottir G, Mukherjee S, Wallon D, Uphill J,  
1073 Aspelund T, Cantwell LB, Garzía F, Galimberti D, Hofer  
1074 E, Butkiewicz M, Fin B, Scarpini E, Sarnowski C, Bush  
1075 WS, Meslage S, Kornhuber J, White CC, Song Y, Barber  
1076 RC, Engelborghs S, Sordon S, Vojnovic D, Adams PM,  
1077 Vandenbergh R, Mayhaus M, Cupples LA, Albert MS, De  
1078 Deyn PP, Gu W, Himali JJ, Beekly D, Squassina A, Hart-  
1079 mann AM, Orellana A, Blacker D, Rodriguez-Rodriguez  
1080 E, Lovestone S, Garcia ME, Doody RS, Munoz-Fernandez  
1081 C, Sussams R, Lin H, Fairchild TJ, Benito YA, Holmes C,  
1082 Karamujčić-Comić H, Frosch MP, Thonberg H, Maier W,  
1083 Roschupkin G, Ghetti B, Giedraitis V, Kawalia A, Li S,  
1084 Huebinger RM, Kilander L, Moebus S, Hernández I, Kam-  
1085 boh MI, Brundin R, Turton J, Yang Q, Katz MJ, Concari  
1086  
1087  
1088  
1089  
1090  
1091  
1092

- 1093 L, Lord J, Beiser AS, Keene CD, Helisalimi S, Kloszewska  
1094 I, Kukull WA, Koivisto AM, Lynch A, Tárraga L, Larson  
1095 EB, Haapasalo A, Lawlor B, Mosley TH, Lipton RB, Sol-  
1096 frizzi V, Gill M, Longstreth WT, Montine TJ, Frisardi V,  
1097 Diez-Fairen M, Rivadeneira F, Petersen RC, Deramecourt  
1098 V, Alvarez I, Salani F, Ciaramella A, Boerwinkle E, Reiman  
1099 EM, Fiévet N, Rotter JI, Reisch JS, Hanon O, Cupidi C,  
1100 Andre Uitterlinden AG, Royall DR, Dufouil C, Maletta RG,  
1101 de Rojas I, Sano M, Brice A, Cecchetti R, George-Hyslop  
1102 PS, Ritchie K, Tsolaki M, Tsuang DW, Dubois B, Craig D,  
1103 Wu C-K, Soininen H, Avramidou D, Albin RL, Fratiglioni  
1104 L, Germanou A, Apostolova LG, Keller L, Koutroumani M,  
1105 Arnold SE, Panza F, Gkatzima O, Asthana S, Hannequin D,  
1106 Whitehead P, Atwood CS, Caffarra P, Hampel H, Quintela  
1107 I, Carracedo Á, Lannfelt L, Rubinsztein DC, Barnes LL,  
1108 Pasquier F, Frolich L, Barral S, McGuinness B, Beach TG,  
1109 Johnston JA, Becker JT, Passmore P, Bigio EH, Schott JM,  
1110 Bird TD, Warren JD, Boeve BF, Lupton MK, Bowen JD,  
1111 Proitsi P, Boxer A, Powell JF, Burke JR, Kauwe JSK, Burns  
1112 JM, Mancuso M, Buxbaum JD, Bonuccelli U, Cairns NJ,  
1113 McQuillin A, Cao C, Livingston G, Carlson CS, Bass NJ,  
1114 Carlsson CM, Hardy J, Carney RM, Bras J, Carrasquillo  
1115 MM, Guerreiro R, Allen M, Chui HC, Fisher E, Masullo C,  
1116 Crocco EA, DeCarli C, Biscoglio G, Dick M, Ma L, Duara  
1117 R, Graff-Radford NR, Evans DA, Hodges A, Faber KM,  
1118 Scherer M, Fallon KB, Riemenschneider M, Fardo DW,  
1119 Heun R, Farlow MR, Kolsch H, Ferris S, Leber M, Foroud  
1120 TM, Heuser I, Galasko DR, Giegling I, Gearing M, Hull M,  
1121 Geschwind DH, Gilbert JR, Morris J, Green RC, Mayo K,  
1122 Growdon JH, Feulner T, Hamilton RL, Harrell LE, Driichel  
1123 D, Honig LS, Cushion TD, Huentelman MJ, Hollingworth  
1124 P, Hulette CM, Hyman BT, Marshall R, Jarvik GP, Meggy  
1125 A, Abner E, Menzies GE, Jin L-W, Leonenko G, Real LM,  
1126 Jun GR, Baldwin CT, Grozeva D, Karydas A, Russo G,  
1127 Kaye JA, Kim R, Jessen F, Kowall NW, Vellas B, Kramer  
1128 JH, Vardy E, LaFerla FM, Jöckel K-H, Lah JJ, Dichgans  
1129 M, Leverenz JB, Mann D, Levey AI, Pickering-Brown S,  
1130 Lieberman AP (2019) Genetic meta-analysis of diagnosed  
1131 Alzheimer's disease identifies new risk loci and implicates  
1132 A $\beta$ , tau, immunity and lipid processing. *Nat Genet* **51**,  
1133 414-430.
- [31] Sims R, van der Lee SJ, Naj AC, Bellenguez C,  
1134 Badarinarayan N, Jakobsdottir J, Kunkle BW, Boland  
1135 A, Raybould R, Bis JC, Martin ER, Grenier-Boley B,  
1136 Heilmann-Heimbach S, Chouraki V, Kuzma AB, Sleegers  
1137 K, Vronskaya M, Ruiz A, Graham RR, Olaso R, Hoffmann  
1138 P, Grove ML, Vardarajan BN, Hiltunen M, Nothen MM,  
1139 White CC, Hamilton-Nelson KL, Epelbaum J, Maier W,  
1140 Choi S-H, Beecham GW, Dulury C, Herms S, Smith AV,  
1141 Funk CC, Derbois C, Forstner AJ, Ahmad S, Li H, Bacq  
1142 D, Harold D, Satizabal CL, Valladares O, Squassina A,  
1143 Thomas R, Brody JA, Qu L, Sanchez-Juan P, Morgan T,  
1144 Wolters FJ, Zhao Y, Garcia FS, Denning N, Fornage M,  
1145 Malamon J, Naranjo MCD, Majounie E, Mosley TH, Dom-  
1146 broski B, Wallon D, Lupton MK, Dupuis J, Whitehead P,  
1147 Fratiglioni L, Medway C, Jian X, Mukherjee S, Keller L,  
1148 Brown K, Lin H, Cantwell LB, Panza F, McGuinness B,  
1149 Moreno-Grau S, Burgess JD, Solfrizzi V, Proitsi P, Adams  
1150 HH, Allen M, Seripa D, Pastor P, Cupples LA, Price ND,  
1151 Hannequin D, Frank-Garcia A, Levy D, Chakrabarty P, Caf-  
1152 farra P, Giegling I, Beiser AS, Giedraitis V, Hampel H,  
1153 Garcia ME, Wang X, Lannfelt L, Mecocci P, Eiriksdottir  
1154 G, Crane PK, Pasquier F, Boccardi V, Henandez I, Barber  
1155 RC, Scherer M, Tárraga L, Adams PM, Leber M, Chen Y,  
1156 Albert MS, Riedel-Heller S, Emilsson V, Beekly D, Braae  
1157 A, Schmidt R, Blacker D, Masullo C, Schmidt H, Doody RS,  
1158 Spalletta G, Longstreth WTJ, Fairchild TJ, Bossù P, López  
1159 OL, Frosch MP, Sacchinelli E, Ghetti B, Yang Q, Huebinger  
1160 RM, Jessen F, Li S, Kamboh MI, Morris J, Sotolongo-Grau  
1161 O, Katz MJ, Corcoran C, Dunstan M, Braddel A, Thomas C,  
1162 Meggy A, Marshall R, Gerrish A, Chapman J, Aguilar M,  
1163 Taylor S, Hill M, Fairen MD, Hodges A, Vellas B, Soininen  
1164 H, Kloszewska I, Daniilidou M, Uphill J, Patel Y, Hughes  
1165 JT, Lord J, Turton J, Hartmann AM, Cecchetti R, Fenoglio  
1166 C, Serpente M, Arcaro M, Caltagirone C, Orfei MD, Cia-  
1167 ramella A, Pichler S, Mayhaus M, Gu W, Lleo A, Fortea J,  
1168 Blesa R, Barber IS, Brookes K, Cupidi C, Maletta RG, Car-  
1169 rell D, Sorbi S, Moebus S, Urbano M, Pilotto A, Kornhuber  
1170 J, Bosco P, Todd S, Craig D, Johnston J, Gill M, Lawlor  
1171 B, Lynch A, Fox NC, Hardy J, Albin RL, Apostolova LG,  
1172 Arnold SE, Asthana S, Atwood CS, Baldwin CT, Barnes LL,  
1173 Barral S, Beach TG, Becker JT, Bigio EH, Bird TD, Boeve  
1174 BF, Bowen JD, Boxer A, Burke JR, Burns JM, Buxbaum JD,  
1175 Cairns NJ, Cao C, Carlson CS, Carlsson CM, Carney RM,  
1176 Carrasquillo MM, Carroll SL, Diaz CC, Chui HC, Clark  
1177 DG, Cribbs DH, Crocco EA, DeCarli C, Dick M, Duara R,  
1178 Evans DA, Faber KM, Fallon KB, Fardo DW, Farlow MR,  
1179 Ferris S, Foroud TM, Galasko DR, Gearing M, Geschwind  
1180 DH, Gilbert JR, Graff-Radford NR, Green RC, Growdon  
1181 JH, Hamilton RL, Harrell LE, Honig LS, Huentelman MJ,  
1182 Hulette CM, Hyman BT, Jarvik GP, Abner E, Jin L-W, Jun  
1183 G, Karydas A, Kaye JA, Kim R, Kowall NW, Kramer JH,  
1184 LaFerla FM, Lah JJ, Leverenz JB, Levey AI, Li G, Lieber-  
1185 man AP, Lunetta KL, Lyketsos CG, Marson DC, Martiniuk  
1186 F, Mash DC, Masliah E, McCormick WC, McCurry SM,  
1187 McDavid AN, McKee AC, Mesulam M, Miller BL, Miller  
1188 CA, Miller JW, Morris JC, Murrell JR, Myers AJ, O'Bryant  
1189 S, Olichney JM, Pankratz VS, Parisi JE, Paulson HL, Perry  
1190 W, Peskind E, Pierce A, Poon WW, Potter H, Quinn JF, Raj  
1191 A, Raskind M, Reisberg B, Reitz C, Ringman JM, Roberson  
1192 ED, Rogava E, Rosen HJ, Rosenberg RN, Sager MA,  
1193 Saykin AJ, Schneider JA, Schneider LS, Seeley WW, Smith  
1194 AG, Sonnen JA, Spina S, Stern RA, Swerdlow RH, Tanzi  
1195 RE, Thornton-Wells TA, Trojanowski JQ, Troncoso JC, Van  
1196 Deerlin VM, Van Eldik LJ, Vinters HV, Vonsattel JP, Wein-  
1197 traub S, Welsh-Bohmer KA, Wilhelmsen KC, Williamson J,  
1198 Wingo TS, Woltjer RL, Wright CB, Yu C-E, Yu L, Garzia F,  
1199 Golamtaully F, Septier G, Engelborghs S, Vandenberghe R,  
1200 De Deyn PP, Fernandez CM, Benito YA, Thonberg H, Forsell  
1201 C, Lilius L, Kinhult-Stahlbom A, Kilander L, Brundin R,  
1202 Concari L, Helisalimi S, Koivisto AM, Haapasalo A, Derme-  
1203 court V, Fiévet N, Hanon O, Dufouil C, Brice A, Ritchie K,  
1204 Dubois B, Himali JJ, Keene CD, Tschanz J, Fitzpatrick AL,  
1205 Kukull WA, Norton M, Aspelund T, Larson EB, Munger  
1206 R, Rotter JI, LIPTON RB, Bullido MJ, Hofman A, Mon-  
1207 tine TJ, Coto E, Boerwinkle E, Petersen RC, Alvarez V,  
1208 Rivadeneira F, Reiman EM, Gallo M, O'Donnell CJ, Reisch  
1209 JS, Bruni AC, Royall DR, Dichgans M, Sano M, Galimberti  
1210 D, St George-Hyslop P, Scarpini E, Tsuang DW, Mancuso  
1211 M, Bonuccelli U, Winslow AR, Daniele A, Wu C-K, Peters  
1212 O, Nacmias B, Riemenschneider M, Heun R, Brayne C,  
1213 Rubinsztein DC, Bras J, Guerreiro R, Al-Chalabi A, Shaw  
1214 CE, Collinge J, Mann D, Tsolaki M, Clarimon J, Sussams  
1215 R, Lovestone S, O'Donovan MC, Owen MJ, Behrens TW,  
1216 Mead S, Goate AM, Uitterlinden AG, Holmes C, Cruchaga  
1217 C, Ingelsson M, Bennett DA, Powell J, Golde TE, Graff  
1218 C, De Jager PL, Morgan K, Ertekin-Taner N, Combarros  
1219 O, Psaty BM, Passmore P, Younkin SG, Berr C, Gudna-  
1220 son V, Rujescu D, Dickson DW, Dartigues J-F, DeStefano  
1221 AL, Ortega-Cubero S, Hakonarson H, Campion D, Boada  
1222

- 1223 M, Kauwe JK, Farrer LA, Van Broeckhoven C, Ikram MA, 1288  
 1224 Jones L, Haines JL, Tzourio C, Launer LJ, Escott-Price V, 1289  
 1225 Mayeux R, Deleuze J-F, Amin N, Holmans PA, Pericak- 1290  
 1226 Vance MA, Amouyel P, van Duijn CM, Ramirez A, Wang 1291  
 1227 L-S, Lambert J-C, Seshadri S, Williams J, Schellenberg 1292  
 1228 GD (2017) Rare coding variants in *PLCG2*, *ABI3*, and 1293  
 1229 *TREM2* implicate microglial-mediated innate immunity in 1294  
 1230 Alzheimer's disease. *Nat Genet* **49**, 1373-1384. 1295
- 1231 [32] Small BJ, Rosnick CB, Fratiglioni L, Bäckman L (2004) 1296  
 1232 Apolipoprotein E and cognitive performance: A meta- 1297  
 1233 analysis. *Psychol Aging* **19**, 592-600. 1298
- 1234 [33] Wisdom NM, Callahan JL, Hawkins KA (2011) The effects 1299  
 1235 of apolipoprotein E on non-impaired cognitive functioning: 1300  
 1236 A meta-analysis. *Neurobiol Aging* **32**, 63-74. 1301
- 1237 [34] Andrews S, McFall GP (2017) Association of non-APOE 1302  
 1238 Alzheimer's genetic risk loci with cognitive aging: A sys- 1303  
 1239 tematic review. PROSPERO, CRD42017075685. 1304
- 1240 [35] Cochrane (2016) *Covidence*. 1305
- 1241 [36] Lezak MD, Howieson DB, Loring DW, Fischer JS (2004) 1306  
 1242 Neuropsychological assessment (4<sup>th</sup> ed). Oxford University 1307  
 1243 Press, New York. 1308
- 1244 [37] Sohani ZN, Meyre D, de Souza RJ, Joseph PG, Gandhi M, 1309  
 1245 Dennis BB, Norman G, Anand SS (2015) Assessing the 1310  
 1246 quality of published genetic association studies in meta- 1311  
 1247 analyses: The quality of genetic studies (Q-Genie) tool. 1312  
 1248 *BMC Genet* **16**, 50. 1313
- 1249 [38] Savage JE, Jansen PR, Stringer S, Watanabe K, Bryois J, 1314  
 1250 de Leeuw CA, Nagel M, Awasthi S, Barr PB, Coleman JRI, 1315  
 1251 Grasby KL, Hammerschlag AR, Kaminski JA, Karlsson R, 1316  
 1252 Krapohl E, Lam M, Nygaard M, Reynolds CA, Trampush 1317  
 1253 JW, Young H, Zabaneh D, Hagg S, Hansell NK, Karlsson 1318  
 1254 IK, Linnarsson S, Montgomery GW, Munoz-Manchado AB, 1319  
 1255 Quinlan EB, Schumann G, Skene NG, Webb BT, White T, 1320  
 1256 Arking DE, Avramopoulos D, Bilder RM, Bitsios P, Burdick 1321  
 1257 KE, Cannon TD, Chiba-Falek O, Christoforou A, Cirulli ET, 1322  
 1258 Congdon E, Corvin A, Davies G, Deary IJ, DeRosse P, Dick- 1323  
 1259 inson D, Djurovic S, Donohoe G, Conley ED, Eriksson JG, 1324  
 1260 Espeseth T, Freimer NA, Giakoumaki S, Giegling I, Gill M, 1325  
 1261 Glahn DC, Hariri AR, Hatzimanolis A, Keller MC, Knowles 1326  
 1262 E, Koltai D, Konte B, Lahti J, Le Hellard S, Lencz T, Liewald 1327  
 1263 DC, London E, Lundervold AJ, Malhotra AK, Melle I, Morris 1328  
 1264 D, Need AC, Ollier W, Palotie A, Payton A, Pendleton N, 1329  
 1265 Poldrack RA, Raikonen K, Reinvang I, Roussos P, Rujescu 1330  
 1266 D, Sabb FW, Scult MA, Smeland OB, Smyrnis N, Starr JM, 1331  
 1267 Steen VM, Stefanis NC, Straub RE, Sundet K, Tiemeier H, 1332  
 1268 Voineskos AN, Weinberger DR, Widen E, Yu J, Abecasis 1333  
 1269 G, Andreassen OA, Breen G, Christiansen L, Debrabant B, 1334  
 1270 Dick DM, Heinz A, Hjerling-Leffler J, Ikram MA, Kendler 1335  
 1271 KS, Martin NG, Medland SE, Pedersen NL, Plomin R, Pold- 1336  
 1272 erman TJC, Ripke S, van der Sluis S, Sullivan PF, Vrieze SI, 1337  
 1273 Wright MJ, Posthuma D (2018) Genome-wide association 1338  
 1274 meta-analysis in 269,867 individuals identifies new genetic 1339  
 1275 and functional links to intelligence. *Nat Genet* **50**, 912-919. 1340
- 1276 [39] Davies G, Lam M, Harris SE, Trampush JW, Luciano M, 1341  
 1277 Hill WD, Hagenaars SP, Ritchie SJ, Marioni RE, Fawns- 1342  
 1278 Ritchie C, Liewald DCM, Okely JA, Ahola-Olli AV, Barnes 1343  
 1279 CLK, Bertram L, Bis JC, Burdick KE, Christoforou A, 1344  
 1280 DeRosse P, Djurovic S, Espeseth T, Giakoumaki S, Gid- 1345  
 1281 daluru S, Gustavson DE, Hayward C, Hofer E, Ikram MA, 1346  
 1282 Karlsson R, Knowles E, Lahti J, Leber M, Li S, Mather 1347  
 1283 KA, Melle I, Morris D, Oldmeadow C, Palviainen T, Payton 1348  
 1284 A, Pazoki R, Petrovic K, Reynolds CA, Sargurupremraj 1349  
 1285 M, Scholz M, Smith JA, Smith AV, Terzikhan N, Thala- 1350  
 1286 muthu A, Trompet S, van der Lee SJ, Ware EB, Windham 1351  
 1287 BG, Wright MJ, Yang J, Yu J, Ames D, Amin N, Amouyel 1352
- P, Andreassen OA, Armstrong NJ, Assareh AA, Attia JR, 1288  
 Attix D, Avramopoulos D, Bennett DA, Bohmer AC, Boyle 1289  
 PA, Brodaty H, Campbell H, Cannon TD, Cirulli ET, Cong- 1290  
 don E, Conley ED, Corley J, Cox SR, Dale AM, Dehghan 1291  
 A, Dick D, Dickinson D, Eriksson JG, Evangelou E, Faul 1292  
 JD, Ford I, Freimer NA, Gao H, Giegling I, Gillespie NA, 1293  
 Gordon SD, Gottesman RF, Griswold ME, Gudnason V, 1294  
 Harris TB, Hartmann AM, Hatzimanolis A, Heiss G, Holl- 1295  
 iday EG, Joshi PK, Kahonen M, Kardia SLR, Karlsson I, 1296  
 Kleiheidam L, Knopman DS, Kochan NA, Konte B, Kwok 1297  
 JB, Le Hellard S, Lee T, Lehtimäki T, Li S-C, Liu T, Koini M, 1298  
 London E, Longstreth WTJ, López OL, Loukola A, Luck 1299  
 T, Lundervold AJ, Lundquist A, Lyytikäinen L-P, Martin 1300  
 NG, Montgomery GW, Murray AD, Need AC, Noordam 1301  
 R, Nyberg L, Ollier W, Papenberg G, Pattie A, Polasek O, 1302  
 Poldrack RA, Psaty BM, Reppermund S, Riedel-Heller SG, 1303  
 Rose RJ, Rotter JJ, Roussos P, Rovio SP, Saba Y, Sabb FW, 1304  
 Sachdev PS, Satizabal CL, Schmid M, Scott RJ, Scult MA, 1305  
 Simino J, Slagboom PE, Smyrnis N, Soumare A, Stefanis 1306  
 NC, Stott DJ, Straub RE, Sundet K, Taylor AM, Taylor KD, 1307  
 Tzoulaki I, Tzourio C, Uitterlinden A, Vitart V, Voineskos 1308  
 AN, Kaprio J, Wagner M, Wagner H, Weinhold L, Wen KH, 1309  
 Widen E, Yang Q, Zhao W, Adams HHH, Arking DE, Bilder 1310  
 RM, Bitsios P, Boerwinkle E, Chiba-Falek O, Corvin A, De 1311  
 Jager PL, Debette S, Donohoe G, Elliott P, Fitzpatrick AL, 1312  
 Gill M, Glahn DC, Hagg S, Hansell NK, Hariri AR, Ikram 1313  
 MK, Jukema JW, Vuoksima E, Keller MC, Kremen WS, 1314  
 Launer L, Lindenberg U, Palotie A, Pedersen NL, Pendle- 1315  
 ton N, Porteous DJ, Raikonen K, Raitakari OT, Ramirez 1316  
 A, Reinvang I, Rudan I, Rujescu D, Schmidt R, Schmidt 1317  
 H, Schofield PW, Schofield PR, Starr JM, Steen VM, Trol- 1318  
 lor JN, Turner ST, van Duijn CM, Villringer A, Weinberger 1319  
 DR, Weir DR, Wilson JF, Malhotra A, McIntosh AM, Gale 1320  
 CR, Seshadri S, Mosley THJ, Bressler J, Lencz T, Deary 1321  
 IJ (2018) Study of 300,486 individuals identifies 148 inde- 1322  
 pendent genetic loci influencing general cognitive function. 1323  
*Nat Commun* **9**, 2098. 1324
- [40] Hill WD, Marioni RE, Maghziyan O, Ritchie SJ, Hagenaars 1325  
 SP, McIntosh AM, Gale CR, Davies G, Deary IJ (2018) A 1326  
 combined analysis of genetically correlated traits identifies 1327  
 187 loci and a role for neurogenesis and myelination in 1328  
 intelligence. *Mol Psychiatry* **15**, 201. 1329
- [41] Andrews SJ, Das D, Anstey KJ, Easteal S (2017) Late 1330  
 onset Alzheimer's disease risk variants in cognitive decline: 1331  
 The PATH Through Life Study. *J Alzheimers Dis* **57**, 1332  
 423-436. 1333
- [42] Carrasquillo MM, Crook JE, Pedraza O, Thomas CS, 1334  
 Pankratz VS, Allen M, Nguyen T, Malphrus KG, Ma L, 1335  
 Bisceglia GD, Roberts RO, Lucas JA, Smith GE, Ivnik RJ, 1336  
 Machulda MM, Graff-Radford NR, Petersen RC, Younkin 1337  
 SG, Ertekin-Taner N (2015) Late-onset Alzheimer's risk 1338  
 variants in memory decline, incident mild cognitive impair- 1339  
 ment, and Alzheimer's disease. *Neurobiol Aging* **36**, 1340  
 60-67. 1341
- [43] Engelman CD, Kosciak RL, Jonaitis EM, Okonkwo OC, 1342  
 Hermann BP, La Rue A, Sager MA (2013) Interaction 1343  
 between two cholesterol metabolism genes influences mem- 1344  
 ory: Findings from the Wisconsin Registry for Alzheimer's 1345  
 Prevention. *J Alzheimers Dis* **36**, 749-757. 1346
- [44] Bressler J, Mosley TH, Penman A, Gottesman RF, Wind- 1347  
 ham BG, Knopman DS, Wruck LM, Boerwinkle E (2017) 1348  
 Genetic variants associated with risk of Alzheimer's disease 1349  
 contribute to cognitive change in midlife: The Atheroscle- 1350  
 rosis Risk in Communities Study. *Am J Med Genet B 1351  
 Neuropsychiatr Genet* **174**, 269-282. 1352

- 1353 [45] Nettiksimmons J, Tranah G, Evans DS, Yokoyama JS, Yaffe  
1354 K (2016) Gene-based aggregate SNP associations between  
1355 candidate AD genes and cognitive decline. *AGE* **38**, 41. 1418
- 1356 [46] Vivot A, Glymour MM, Tzourio C, Amouyel P, Chene G,  
1357 Dufouil C (2015) Association of Alzheimer's related geno-  
1358 types with cognitive decline in multiple domains: Results  
1359 from the Three-City Dijon study. *Mol Psychiatry* **20**, 1173-  
1360 1178. 1419
- 1361 [47] Hamilton G, Harris SE, Davies G, Liewald DC, Tenesa A,  
1362 Starr JM, Porteous D, Deary IJ (2011) Alzheimer's disease  
1363 genes are associated with measures of cognitive ageing in  
1364 the lothian birth cohorts of 1921 and 1936. *Int J Alzheimers*  
1365 *Dis* **2011**, 505984. 1420
- 1366 [48] Verhaaren BFJ, Vernooij MW, Koudstaal PJ, Uitterlinden  
1367 AG, van Duijn CM, Hofman A, Breteler MMB, Ikram MA  
1368 (2013) Alzheimer's disease genes and cognition in the non-  
1369 demented general population. *Biol Psychiatry* **73**, 429-434. 1421
- 1370 [49] Zhang C, Pierce BL (2014) Genetic susceptibility to accel-  
1371 erated cognitive decline in the US Health and Retirement  
1372 Study. *Neurobiol Aging* **35**, 1512.e11-8. 1422
- 1373 [50] Hagenaars SP, Cox SR, Hill WD, Davies G, Liewald DCM,  
1374 CHARGE consortium Cognitive Working Group, Harris  
1375 SE, McIntosh AM, Gale CR, Deary IJ (2017) Genetic con-  
1376 tributions to Trail Making Test performance in UK Biobank.  
1377 *Mol Psychiatry* **23**, 1575-1583. 1423
- 1378 [51] Thambisetty M, Beason-Held LL, An Y, Kraut M, Nalls M,  
1379 Hernandez DG, Singleton AB, Zonderman AB, Ferrucci L,  
1380 Lovestone S, Resnick SM (2013) Alzheimer risk variant  
1381 CLU and brain function during aging. *Biol Psychiatry* **73**,  
1382 399-405. 1424
- 1383 [52] Pedraza O, Allen M, Jennette K, Carrasquillo M, Crook J,  
1384 Serie D, Pankratz VS, Palusak R, Nguyen T, Malphrus K,  
1385 Ma L, Biscoglio G, Roberts RO, Lucas JA, Ivnik RJ, Smith  
1386 GE, Graff-Radford NR, Petersen RC, Younkin SG, Ertekin-  
1387 Taner N (2014) Evaluation of memory endophenotypes for  
1388 association with CLU, CR1, and PICALM variants in black  
1389 and white subjects. *Alzheimers Dement* **10**, 205-213. 1425
- 1390 [53] Sweet RA, Seltman H, Emanuel JE, López OL, Becker JT,  
1391 Bis JC, Weamer EA, DeMichele-Sweet MAA, Kuller LH  
1392 (2012) Effect of Alzheimer's disease risk genes on trajec-  
1393 tories of cognitive function in the Cardiovascular Health  
1394 Study. *Am J Psychiatry* **169**, 954-962. 1426
- 1395 [54] Mengel-From J, Christensen K, McGue M, Christiansen L  
1396 (2011) Genetic variations in the CLU and PICALM genes  
1397 are associated with cognitive function in the oldest old.  
1398 *Neurobiol Aging* **32**, 554.e7-11. 1427
- 1399 [55] Mengel-From J, Thinggaard M, Lindahl-Jacobsen R,  
1400 McGue M, Christensen K, Christiansen L (2013) CLU  
1401 genetic variants and cognitive decline among elderly and  
1402 oldest old. *PLoS One* **8**, e79105. 1428
- 1403 [56] Dobbie S, Ibrahim-Verbaas CA, Bressler J, Schuur M,  
1404 Smith A, Bis JC, Davies G, Wolf C, Gudnason V, Chib-  
1405 nik LB, Yang Q, DeStefano AL, de Quervain DJF, Srikanth  
1406 V, Lahti J, Grabe HJ, Smith JA, Priebe L, Yu L, Karbalai  
1407 N, Hayward C, Wilson JF, Campbell H, Petrovic K, For-  
1408 nage M, Chauhan G, Yeo R, Boxall R, Becker J, Stegle  
1409 O, Mather KA, Chouraki V, Sun Q, Rose LM, Resnick S,  
1410 Oldmeadow C, Kirin M, Wright AF, Jonsdottir MK, Au R,  
1411 Becker A, Amin N, Nalls MA, Turner ST, Kardia SLR, Oos-  
1412 tra B, Windham G, Coker LH, Zhao W, Knopman DS, Heiss  
1413 G, Griswold ME, Gottesman RF, Vitart V, Hastie ND, Zgaga  
1414 L, Rudan I, Polasek O, Holliday EG, Schofield P, Choi S-H,  
1415 Tanaka T, An Y, Perry RT, Kennedy RE, Sale MM, Wang  
1416 J, Wadley VG, Liewald DC, Ridker PM, Gow AJ, Pattie A,  
1417 Starr JM, Porteous D, Liu X, Thomson R, Armstrong NJ,  
1418 Eiriksdottir G, Assareh AA, Kochan NA, Widen E, Palotie  
1419 A, Hsieh Y-C, Eriksson JG, Vogler C, van Swieten JC, Shul-  
1420 man JM, Beiser A, Rotter J, Schmidt CO, Hoffmann W,  
1421 Nothen MM, Ferrucci L, Attia J, Uitterlinden AG, Amouyel  
1422 P, Dartigues J-F, Amieva H, Raikonen K, Garcia M, Wolf  
1423 PA, Hofman A, Longstreth WTJ, Psaty BM, Boerwinkle  
1424 E, DeJager PL, Sachdev PS, Schmidt R, Breteler MMB,  
1425 Teumer A, López OL, Cichon S, Chasman DI, Grodstein F,  
1426 Muller-Myhsok B, Tzourio C, Papassotiropoulos A, Ben-  
1427 nett DA, Ikram MA, Deary IJ, van Duijn CM, Launer L,  
1428 Fitzpatrick AL, Seshadri S, Mosley THJ (2015) Genome-  
1429 wide studies of verbal declarative memory in nondemented  
1430 older people: The Cohorts for Heart and Aging Research  
1431 in Genomic Epidemiology consortium. *Biol Psychiatry* **77**,  
1432 749-763. 1433
- 1434 [57] Chibnik LB, Shulman JM, Leurgans SE, Schneider JA, Wil-  
1435 son RS, Tran D, Aubin C, Buchman AS, Heward CB, Myers  
1436 AJ, Hardy JA, Huentelman MJ, Corneveaux JJ, Reiman EM,  
1437 Evans DA, Bennett DA, De Jager PL (2011) CR1 is associ-  
1438 ated with amyloid plaque burden and age-related cognitive  
1439 decline. *Ann Neurol* **69**, 560-569. 1434
- 1440 [58] Davies G, Marioni RE, Liewald DC, Hill WD, Hagenaars  
1441 SP, Harris SE, Ritchie SJ, Luciano M, Fawns-Ritchie C,  
1442 Lyall D, Cullen B, Cox SR, Hayward C, Porteous DJ, Evans  
1443 J, McIntosh AM, Gallacher J, Craddock N, Pell JP, Smith  
1444 DJ, Gale CR, Deary IJ (2016) Genome-wide association  
1445 study of cognitive functions and educational attainment in  
1446 UK Biobank ( $N=112\ 151$ ). *Mol Psychiatry* **21**, 758-767. 1435
- 1447 [59] Raj T, Chibnik LB, McCabe C, Wong A, Replogle JM, Yu  
1448 L, Gao S, Unverzagt FW, Stranger B, Murrell J, Barnes L,  
1449 Hendrie HC, Foroud T, Krichevsky A, Bennett DA, Hall  
1450 KS, Evans DA, De Jager PL (2016) Genetic architecture of  
1451 age-related cognitive decline in African Americans. *Neuro*  
1452 *Genet* **3**, e125. 1436
- 1453 [60] Sniekers S, Stringer S, Watanabe K, Jansen PR, Coleman  
1454 JRI, Krapohl E, Taskesen E, Hammerschlag AR, Okbay A,  
1455 Zabaneh D, Amin N, Breen G, Cesarini D, Chabris CF,  
1456 Iacono WG, Ikram MA, Johannesson M, Koellinger P, Lee  
1457 JJ, Magnusson PKE, McGue M, Miller MB, Ollier WER,  
1458 Payton A, Pendleton N, Plomin R, Rietveld CA, Tiemeier  
1459 H, van Duijn CM, Posthuma D (2017) Genome-wide asso-  
1460 ciation meta-analysis of 78,308 individuals identifies new  
1461 loci and genes influencing human intelligence. *Nat Genet*  
1462 **49**, 1107-1112. 1437
- 1463 [61] Davies G, Armstrong N, Bis JC, Bressler J, Chouraki V,  
1464 Giddaluru S, Hofer E, Ibrahim-Verbaas CA, Kirin M, Lahti  
1465 J, van der Lee SJ, Le Hellard S, Liu T, Marioni RE, Old-  
1466 meadow C, Postmus I, Smith AV, Smith JA, Thalamuthu  
1467 A, Thomson R, Vitart V, Wang J, Yu L, Zgaga L, Zhao  
1468 W, Boxall R, Harris SE, Hill WD, Liewald DC, Luciano  
1469 M, Adams H, Ames D, Amin N, Amouyel P, Assareh AA,  
1470 Au R, Becker JT, Beiser A, Berr C, Bertram L, Boerwin-  
1471 kle E, Buckley BM, Campbell H, Corley J, De Jager PL,  
1472 Dufouil C, Eriksson JG, Espeseth T, Faul JD, Ford I, Scot-  
1473 land G, Gottesman RF, Griswold ME, Gudnason V, Harris  
1474 TB, Heiss G, Hofman A, Holliday EG, Huffman J, Kardia  
1475 SLR, Kochan N, Knopman DS, Kwok JB, Lambert JC, Lee  
1476 T, Li G, Li S-C, Lottfelder M, Lopez OL, Lundervold AJ,  
1477 Lundqvist A, Mather KA, Mirza SS, Nyberg L, Oostra BA,  
1478 Palotie A, Papenberg G, Pattie A, Petrovic K, Polasek O,  
1479 Psaty BM, Redmond P, Reppermund S, Rotter JJ, Schmidt  
1480 H, Schuur M, Schofield PW, Scott RJ, Steen VM, Stott DJ,  
1481 van Swieten JC, Taylor KD, Trollor J, Trompet S, Uitter-  
1482 linden AG, Weinstein G, Widen E, Windham BG, Jukema  
1483 JW, Wright AF, Wright MJ, Yang Q, Amieva H, Attia JR,

- 1483 Bennett DA, Brodaty H, de Craen AJM, Hayward C, Ikram  
1484 MA, Lindenberg U, Nilsson L-G, Porteous DJ, Raikonen  
1485 K, Reinvang I, Rudan I, Sachdev PS, Schmidt R, Schofield  
1486 PR, Srikanth V, Starr JM, Turner ST, Weir DR, Wilson JF,  
1487 van Duijn C, Launer L, Fitzpatrick AL, Seshadri S, Mosley  
1488 THJ, Deary IJ (2015) Genetic contributions to variation  
1489 in general cognitive function: A meta-analysis of genome-  
1490 wide association studies in the CHARGE consortium ( $N=53$   
1491 949). *Mol Psychiatry* **20**, 183-192.
- [62] Houlihan LM, Harris SE, Luciano M, Gow AJ, Starr JM,  
1493 Visscher PM, Deary IJ (2009) Replication study of candi-  
1494 date genes for cognitive abilities: The Lothian Birth Cohort  
1495 1936. *Genes Brain Behav* **8**, 238-247.
- [63] Liang Y, Li H, Lv C, Shu N, Chen K, Li X, Zhang J,  
1497 Hu L, Zhang Z (2015) Sex moderates the effects of the  
1498 Sor11 gene rs2070045 polymorphism on cognitive impair-  
1499 ment and disruption of the cingulum integrity in healthy  
1500 elderly. *Neuropsychopharmacology* **40**, 2487-2487.
- [64] Li H, Lv CL, Yang CS, Wei DF, Chen KW, Li SW, Zhang  
1502 ZJ (2017) SORL1 rs1699102 polymorphism modulates age-  
1503 related cognitive decline and gray matter volume reduction  
1504 in non-demented individuals. *Eur J Neurol* **24**, 187-194.
- [65] Liu F, Ikram MA, Janssens ACJW, Schuur M, de Koning I,  
1506 Isaacs A, Struchalin M, Uitterlinden AG, Dunnen den JT,  
1507 Slegers K, Bettens K, Van Broeckhoven C, van Swieten J,  
1508 Hofman A, Oostra BA, Aulchenko YS, Breteler MMB, van  
1509 Duijn CM (2009) A study of the SORL1 gene in Alzheimer's  
1510 disease and cognitive function. *J Alzheimers Dis* **18**, 51-64.
- [66] Reynolds CA, Zavala C, Gatz M, Vie L, Johansson B, Mal-  
1512 mberg B, Ingelsson E, Prince JA, Pedersen NL (2013) Sortilin  
1513 receptor 1 predicts longitudinal cognitive change. *Neurobiol*  
1514 *Aging* **34**, 1710.e11-1710.e18.
- [67] Liu Y, Yu J-T, Wang H-F, Hao X-K, Yang Y-F, Jiang  
1516 T, Zhu X-C, Cao L, Zhang D-Q, Tan L (2014) Associa-  
1517 tion between NME8 locus polymorphism and cognitive  
1518 decline, cerebrospinal fluid and neuroimaging biomarkers  
1519 in Alzheimer's disease. *PLoS One* **9**, e114777.
- [68] Darst BF, Koscik RL, Racine AM, Oh JM, Krause RA,  
1520 Carlsson CM, Zetterberg H, Blennow K, Christian BT,  
1521 Bendlin BB, Okonkwo OC, Hogan KJ, Hermann BP,  
1522 Sager MA, Asthana S, Johnson SC, Engelman CD (2017)  
1523 Pathway-specific polygenic risk scores as predictors of  
1524 amyloid- $\beta$  deposition and cognitive function in a sample  
1525 at increased risk for Alzheimer's disease. *J Alzheimers Dis*  
1526 **55**, 473-484.
- [69] Christoforou A, Espeseth T, Davies G, Fernandes CPD,  
1528 Giddaluru S, Mattheisen M, Tenesa A, Harris SE, Liewald  
1529 DC, Payton A, Ollier W, Horan M, Pendleton N, Haggarty  
1530 P, Djurovic S, Herms S, Hoffman P, Cichon S, Starr JM,  
1531 Lundervold A, Reinvang I, Steen VM, Deary IJ, Le Hel-  
1532 lard S (2014) GWAS-based pathway analysis differentiates  
1533 between fluid and crystallized intelligence. *Genes Brain*  
1534 *Behav* **13**, 663-674.
- [70] Ferencz B, Jonsson Laukka E, Welmer A-K, Kalpouzos  
1536 G, Angleman S, Keller L, Graff C, Lovden M, Backman  
1537 L (2014) The benefits of staying active in old age: Physi-  
1538 cal activity counteracts the negative influence of PICALM,  
1539 BIN1, and CLU risk alleles on episodic memory function-  
1540 ing. *Psychol Aging* **29**, 440-449.
- [71] Marden JR, Mayeda ER, Walter S, Vivot A, Tchetsgen  
1542 Tchetsgen EJ, Kawachi I, Glymour MM (2016) Using an  
1543 Alzheimer disease polygenic risk score to predict mem-  
1544 ory decline in black and white americans over 14 years of  
1545 follow-up. *Alzheimer Dis Assoc Disord* **30**, 195-202.
- [72] Mormino EC, Sperling RA, Holmes AJ, Buckner RL, De  
1547 Jager PL, Smoller JW, Sabuncu MR, Alzheimer's Disease  
1548 Neuroimaging Initiative (2016) Polygenic risk of Alzheimer  
1549 disease is associated with early- and late-life processes.  
1550 *Neurology* **87**, 481-488.
- [73] Liebers DT, Pirooznia M, Seiffudin F, Musliner KL, Zandi  
1552 PP, Goes FS (2016) Polygenic risk of schizophrenia and  
1553 cognition in a population-based survey of older adults.  
1554 *Schizophr Bull* **42**, 984-991.
- [74] Marioni RE, Campbell A, Hagenaars SP, Nagy R, Amador  
1556 C, Hayward C, Porteous DJ, Visscher PM, Deary IJ (2017)  
1557 Genetic stratification to identify risk groups for Alzheimer's  
1558 disease. *J Alzheimers Dis* **57**, 275-283.
- [75] Ge T, Sabuncu MR, Smoller JW, Sperling RA, Mormino  
1560 EC, for the Alzheimer's Disease Neuroimaging Initiative  
1561 (2018) Dissociable influences of APOE $\epsilon$ 4 and polygenic  
1562 risk of AD dementia on amyloid and cognition. *Neurology*  
1563 **90**, e1605-e1612.
- [76] Dudbridge F (2013) Power and predictive accuracy of poly-  
1565 genic risk scores. *PLoS Genet* **9**, e1003348.
- [77] Payton A (2009) The impact of genetic research on our  
1567 understanding of normal cognitive ageing: 1995 to 2009.  
1568 *Neuropsychol Rev* **19**, 451-477.
- [78] De Jager PL, Shulman JM, Chibnik LB, Keenan BT, Raj T,  
1570 Wilson RS, Yu L, Leurgans SE, Tran D, Aubin C, Anderson  
1571 CD, Biffi A, Corneveaux JJ, Huentelman MJ, Rosand J,  
1572 Daly MJ, Myers AJ, Reiman EM, Bennett DA, Evans DA  
1573 (2012) A genome-wide scan for common variants affecting  
1574 the rate of age-related cognitive decline. *Neurobiol Aging*  
1575 **33**, 1017.e1-1017.e15.
- [79] Lyall DM, Cullen B, Allerhand M, Smith DJ, Mackay  
1577 D, Evans J, Anderson J, Fawns-Ritchie C, McIntosh AM,  
1578 Deary IJ, Pell JP (2016) Cognitive test scores in UK  
1579 Biobank: Data reduction in 480,416 participants and long-  
1580 itudinal stability in 20,346 participants. *PLoS One* **11**,  
1581 e0154222.
- [80] Deary IJ, Penke L, Johnson W (2010) The neuroscience  
1583 of human intelligence differences. *Nat Rev Neurosci* **11**,  
1584 201-211.
- [81] Tombaugh TN, McIntyre NJ (1992) The mini-mental state  
1586 examination: A comprehensive review. *J Am Geriatr Soc*  
1587 **40**, 922-935.
- [82] Hofer SM, Christensen H, Mackinnon AJ, Korten AE, Jorm  
1589 AF, Henderson AS, Easteal S (2002) Change in cognitive  
1590 functioning associated with apoE genotype in a community  
1591 sample of older adults. *Psychol Aging* **17**, 194-208.
- [83] Gross AL, Power MC, Albert MS, Deal JA, Gottesman RF,  
1593 Griswold M, Wruck LM, Mosley TH, Coresh J, Sharrett  
1594 AR, Bandeen-Roche K (2015) Application of latent variable  
1595 methods to the study of cognitive decline when tests change  
1596 over time. *Epidemiology* **26**, 878-887.
- [84] McCoach DB, Black AC, O'Connell AA (2007) Errors of  
1598 inference in structural equation modeling. *Psychol Sch* **44**,  
1599 461-470.
- [85] Knight RG, Tsui HSL, Abraham WC, Skeaff CM, McMa-  
1601 hon JA, Cutfield NJ (2014) Lack of effect of the  
1602 apolipoprotein E epsilon4 genotype on cognition during  
1603 healthy aging. *J Clin Exp Neuropsychol* **36**, 742-750.
- [86] Lim YY, Laws SM, Villemagne VL, Pietrzak RH, Porter  
1605 T, Ames D, Fowler C, Rainey-Smith S, Snyder PJ, Martins  
1606 RN, Salvado O, Bourgeat P, Rowe CC, Masters CL, Maruff  
1607 P (2016) A $\beta$ -related memory decline in APOE  $\epsilon$ 4 noncar-  
1608 riers: Implications for Alzheimer disease. *Neurology* **86**,  
1609 1635-1642.

- 1611 [87] Liao Y-C, Lee W-J, Hwang J-P, Wang Y-F, Tsai C-F, Wang  
1612 P-N, Wang S-J, Fuh J-L (2014) ABCA7 gene and the risk of  
1613 Alzheimer's disease in Han Chinese in Taiwan. *Neurobiol*  
1614 *Aging* **35**, 2423.e7-2423.e13.
- 1615 [88] Gui H, Jiang CQ, Cherny SS, Sham PC, Xu L, Liu B, Jin  
1616 YL, Zhu T, Zhang WS, Thomas GN, Cheng KK, Lam TH  
1617 (2014) Influence of Alzheimer's disease genes on cognitive  
1618 decline: The Guangzhou Biobank Cohort Study. *Neurobiol*  
1619 *Aging* **35**, 2422.e3-8.
- 1620 [89] Davies G, Harris SE, Reynolds CA, Payton A, Knight HM,  
1621 Liewald DC, Lopez LM, Luciano M, Gow AJ, Corley J,  
1622 Henderson R, Murray C, Pattie A, Fox HC, Redmond P,  
1623 Lutz MW, Chiba-Falek O, Linnertz C, Saith S, Haggarty P,  
1624 McNeill G, Ke X, Ollier W, Horan M, Roses AD, Ponting  
1625 CP, Porteous DJ, Tenesa A, Pickles A, Starr JM, Whalley LJ,  
1626 Pedersen NL, Pendleton N, Visscher PM, Deary IJ (2014) A  
1627 genome-wide association study implicates the APOE locus  
1628 in nonpathological cognitive ageing. *Mol Psychiatry* **19**,  
1629 76-87.
- 1630 [90] Barral S, Bird T, Goate A, Farlow MR, Diaz-Arrastia R,  
1631 Bennett DA, Graff-Radford N, Boeve BF, Sweet RA, Stern  
1632 Y, Wilson RS, Foroud T, Ott J, Mayeux R (2012) Geno-  
1633 type patterns at PICALM, CR1, BIN1, CLU, and APOE  
1634 genes are associated with episodic memory. *Neurology* **78**,  
1635 1464-1471.
- 1636 [91] Shulman JM, Chibnik LB, Aubin C, Schneider JA, Bennett  
1637 DA, De Jager PL (2010) Intermediate phenotypes identify  
1638 divergent pathways to Alzheimer's disease. *PLoS One* **5**,  
1639 e11244.
- 1640 [92] McFall GP, Sapkota S, McDermott KL, Dixon RA (2016)  
1641 Risk-reducing Apolipoprotein E and Clusterin genotypes  
1642 protect against the consequences of poor vascular health on  
1643 executive function performance and change in nondemented  
1644 older adults. *Neurobiol Aging* **42**, 91-100.
- 1645 [93] Qiu L, He Y, Tang H, Zhou Y, Wang J, Zhang W, Chen G,  
1646 Zhao F, Ouyang T, Ju B, Li Z, Wang L, Zou L, Gong Q (2016)  
1647 Genetically-mediated grey and white matter alteration in  
1648 normal elderly individuals with the CLU-C allele gene. *Curr*  
1649 *Alzheimer Res* **13**, 1302-1310.
- 1650 [94] Keenan BT, Shulman JM, Chibnik LB, Raj T, Tran D,  
1651 Sabuncu MR, Alzheimer's Disease Neuroimaging Initia-  
1652 tive, Allen AN, Corneveaux JJ, Hardy JA, Huentelman MJ,  
1653 Lemere CA, Myers AJ, Nicholson-Weller A, Reiman EM,  
1654 Evans DA, Bennett DA, De Jager PL (2012) A coding vari-  
1655 ant in CR1 interacts with APOE- $\epsilon$ 4 to influence cognitive  
1656 decline. *Hum Mol Gen* **21**, 2377-2388.
- 1657 [95] Hagenaaers SP, Harris SE, Davies G, Hill WD, Liewald  
1658 DCM, Ritchie SJ, Marioni RE, Fawns-Ritchie C, Cullen B,  
1659 Malik R; METASTROKE Consortium, International Con-  
1660 sortium for Blood Pressure GWAS; SpiroMeta Consortium;  
1661 CHARGE Consortium Pulmonary Group, CHARGE Con-  
1662 sortium Aging and Longevity Group, Worrall BB, Sudlow  
1663 CLM, Wardlaw JM, Gallacher J, Pell J, McIntosh AM,  
1664 Smith DJ, Gale CR, Deary IJ (2016) Shared genetic aeti-  
1665 ology between cognitive functions and physical and mental  
1666 health in UK Biobank ( $N=112\ 151$ ) and 24 GWAS consortia.  
1667 *Mol Psychiatry* **21**, 1624-1632.
- 1668 [96] Harris SE, Davies G, Luciano M, Payton A, Fox HC,  
1669 Haggarty P, Ollier W, Horan M, Porteous DJ, Starr JM,  
1670 Whalley LJ, Pendleton N, Deary IJ (2014) Polygenic risk  
1671 for Alzheimer's disease is not associated with cognitive  
1672 ability or cognitive aging in non-demented older people.  
1673 *J Alzheimers Dis* **39**, 565-574.
- 1674 [97] Liang Y, Li H, Lv C, Shu N, Chen K, Li X, Zhang J,  
1675 Hu L, Zhang Z (2015) Sex moderates the effects of the  
1676 Sor11 gene rs2070045 polymorphism on cognitive impair-  
1677 ment and disruption of the cingulum integrity in healthy  
1678 elderly. *Neuropsychopharmacology* **40**, 1519-1527.